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Abstract 
Background: Human immunodeficiency virus type 1 (HIV‑1) has evolved a complex strategy to overcome the 
immune barriers it encounters throughout an organism thanks to its viral infectivity factor (Vif ), a key protein for HIV‑1 
infectivity and in vivo pathogenesis. Vif interacts with and promotes “apolipoprotein B mRNA‑editing enzyme‑cata‑
lytic, polypeptide‑like 3G” (A3G) ubiquitination and subsequent degradation by the proteasome, thus eluding A3G 
restriction activity against HIV‑1.
Results: We found that cellular histone deacetylase 6 (HDAC6) directly interacts with A3G through its C‑terminal BUZ 
domain (residues 841–1,215) to undergo a cellular co‑distribution along microtubules and cytoplasm. The HDAC6/
A3G complex occurs in the absence or presence of Vif, competes for Vif‑mediated A3G degradation, and accounts 
for A3G steady‑state expression level. In fact, HDAC6 directly interacts with and promotes Vif autophagic clearance, 
thanks to its C‑terminal BUZ domain, a process requiring the deacetylase activity of HDAC6. HDAC6 degrades Vif 
without affecting the core binding factor β (CBF‑β), a Vif‑associated partner reported to be key for Vif‑ mediated A3G 
degradation. Thus HDAC6 antagonizes the proviral activity of Vif/CBF‑β‑associated complex by targeting Vif and 
stabilizing A3G. Finally, in cells producing virions, we observed a clear‑cut correlation between the ability of HDAC6 
to degrade Vif and to restore A3G expression, suggesting that HDAC6 controls the amount of Vif incorporated into 
nascent virions and the ability of HIV‑1 particles of being infectious. This effect seems independent on the presence of 
A3G inside virions and on viral tropism.
Conclusions: Our study identifies for the first time a new cellular complex, HDAC6/A3G, involved in the autophagic 
degradation of Vif, and suggests that HDAC6 represents a new antiviral factor capable of controlling HIV‑1 infective‑
ness by counteracting Vif and its functions.
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Background
APOBEC3G (apolipoprotein B mRNA-editing enzyme-
catalytic, polypeptide-like 3G or A3G) is a member of the 
APOBEC superfamily of cytidine deaminases [1], which 
are thought to restrict human immunodeficiency virus 
type 1 (HIV-1) activity. Following its incorporation into 
nascent virions, A3G exerts its antiviral effects by deami-
nating cytidine to uracil in newly synthesized (−)-strand 
viral DNA, leading to G-to-A invalidating hypermuta-
tions in the (+)-strand viral DNA [2–5]. The DNA repair 
pathway involves uracil-DNA glycosylase while apu-
rinic–apyrimidinic endonuclease degrades A3G-hyper-
mutated viral DNA [6–8]. In contrast, non-degraded 
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hypermutated (+)-strand viral DNA potentially leads 
not only to mutated viral proteins and/or altered reading 
frames, but also to unexpected translation termination 
codons [2, 3, 5, 9–12]. Additionally, A3G also inhib-
its HIV-1 infection by a cytidine deaminase-independ-
ent pathway involving interaction with viral RNA and 
impairment of the reverse transcription and integration 
processes [4, 8, 11, 13–17]. Thus, the ability of A3G to 
interact with different cellular and/or viral RNA and pro-
teins could compromise or promote its anti-HIV-1 func-
tions [18–20]. A3G might, however, diversify the viral 
genome, thereby promoting infectious HIV-1 variants 
and even generating HIV-1 drug-resistant phenotypes 
[21–24]. These data suggest the existence of a complex 
A3G-mediated restrictive function against HIV-1, poten-
tially dependent on a variety of A3G targets [12, 25, 26].
HIV-1 employs a complex strategy to overcome 
immune barriers [27, 28], particularly in target cells, 
through its auxiliary viral genes, such as the viral infec-
tivity factor (Vif ), which is essential for HIV-1 infectivity 
and in  vivo pathogenesis [28–30]. In fact, Vif promotes 
A3G degradation, eluding its restrictive activity against 
HIV-1 [31, 32]. Vif binds to several cellular proteins, such 
as Cullin 5 (Cul5), Elongin B (EloB), EloC, and Rbx2 to 
form a Vif-BC-Cul5 complex, acting as an ubiquitin 
ligase (E3)-like complex [32–36]. This Vif-BC-Cul5 com-
plex targets A3G, via Vif-A3G interactions, thus medi-
ating A3G ubiquitination and subsequent proteasome 
degradation [32–35]. Vif also requires and interacts with 
the core binding factor β (CBF-β), the non-DNA-bind-
ing subunit of a heterodimeric transcription factor, to 
degrade A3G [36–38]. By this mechanism, Vif indirectly 
protects viral DNA from A3G deaminations and avoids 
A3G incorporation into nascent viral particles [32, 39–
41]. Moreover, Vif also negatively controls A3G antiviral 
activity by targeting its mRNA and inhibiting its transla-
tion [40, 42, 43].
We have previously reported that HIV-1 stabilizes 
acetylated microtubules (MT) during early infection, a 
crucial signal for HIV-1 Env-mediated pore fusion for-
mation, viral entry, and infection [44, 45]. Human his-
tone deacetylase 6 (HDAC6) not only inhibits this early 
HIV-1 Env/CD4-mediated signalling, but also viral infec-
tion and replication, in a deacetylase-dependent manner 
[44–46]. Furthermore, HDAC6 promotes the forma-
tion of aggresomes and activates autophagy [47–51]. 
Hence, HDAC6 is involved in the transport and clear-
ance of those ubiquitinated proteins that do not enter 
the proteasome pathway, and that bear unconjugated 
C-terminal diglycine motifs on their ubiquitin-associ-
ated chains [47–52]. In cells where proteasomal clear-
ance is blocked, HDAC6 may also recognize unanchored, 
protein-free polyubiquitin chains. This event activates 
HDAC6-triggered actinomyosin- and autophagy-
dependent aggresome processing of proteins [53]. Thus, 
HDAC6 emerges as a key enzyme for clearing ubiquit-
inated proteins that fail to enter proteasome pathways. In 
fact, HDAC6 presents a Cys/His-rich motif in its C-ter-
minal region [54–56], which interacts in particular with 
ubiquitin and could function as a mono-ubiquitin ligase 
[51, 52, 57–59]. This motif shows significant sequence 
homology with BRCA1-associated protein BRAP2 and 
several ubiquitin-specific proteases, and is known as a 
DAUP (deacetylase-ubiquitin-specific protease) domain 
[60], HUB (HDAC6-, USP3- and BRAP2-related) finger 
[61], ZnF-UBP (ubiquitin C-terminal hydrolase-like zinc 
finger) [57], PAZ (polyubiquitin-associated zinc finger) 
[58], or BUZ (bound to ubiquitin zinc finger) domain 
[47]. Of note, Vif seems to be post-translationally mono-
ubiquitinated, being stable and not recruited by the pro-
teasome-degradative pathway [62, 63].
Considering the anti-HIV-1 and pro-aggresome/
autophagic functions of HDAC6, it is conceivable that 
HDAC6 regulates HIV-1 infection by the interplay of 
A3G and Vif proteins, and the Vif-triggered ubiquitina-
tion and subsequent proteasome degradation of A3G. 
In this study, we show that HDAC6 forms a constitutive 
complex with A3G that competes for Vif-A3G interac-
tion. This new complex accounts for the steady-state 
expression level of A3G, thereby neutralizing Vif-medi-
ated A3G ubiquitination and proteasome degradation, 
and stabilizing Vif-non-targeted A3G. HDAC6 is able to 
establish a ternary complex through binding to A3G and 
Vif at the same time. In fact, HDAC6 interacts with Vif 
and regulates its stability without altering CBF-β. Finally, 
HDAC6 controls HIV-1 infectiveness by regulating the 
incorporation of Vif into nascent virions through the 
induction of its autophagic degradation. This mechanism 
is dependent on the BUZ domain of HDAC6 and requires 
its deacetylase activity.
Altogether, our results pointed out HDAC6 as a new 
protein involved in the antiviral machinery of an HIV-1 
infected cell.
Results
HDAC6 induces Vif degradation, and protects A3G 
from Vif‑mediated degradative activity
To ascertain the ability of HDAC6 to protect A3G against 
Vif-mediated proteasome degradation, we analyzed A3G 
degradation by recombinant Vif in HEK 293T permissive 
cells (lacking A3G), under control conditions (Figure 1a, 
b) or with overexpressed HDAC6 constructs (Figure 1c). 
We observed that Vif degrades A3G in a dose-dependent 
manner, regardless of the A3G-associated tag (Figure 1a, 
b). However, in presence of overexpressed wt-HDAC6 
(Figure  1d), we observed a dose-dependent protective 
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Figure 1 HDAC6 degrades Vif and protects A3G from Vif‑mediated degradation. a, b Top‑A, western blot analysis of different A3G‑tagged proteins 
in cells lacking endogenous A3G expression (control). Bottom a, b, western blot analysis of Vif‑mediated degradation of different A3G‑tagged mole‑
cules. c Schematic representation of EGFP‑ or HA‑tagged wt‑HDAC6 and HDAC6‑ΔBUZ constructs used in this study. The different domains are indi‑
cated: the nuclear localization signal (NLS) and export signal 1 and 2 (NES1/2), the two histone deacetylase domains (hdac 1 and 2) together with 
the SE14 region, and the BUZ domain (adapted from [56]). d Left, western blot of dose‑response effects of EGFP‑wt‑HDAC6 and EGFP‑HDAC6‑ΔBUZ 
(detected by anti‑HDAC6 or anti‑EGFP abs, respectively) on Vif and A3G‑3xHA. Lanes 1, 7 and 2, 8 are controls representing cells overexpressing 
only A3G‑3xHA or A3G‑3xHA together with Vif, respectively. Right, quantitation of western blots regarding EGFP‑HDAC6‑ and EGFP‑HDAC6‑ΔBUZ‑
mediated Vif degradation (top) and A3G protection (bottom). In all western blots, α‑tubulin is the control for total protein. When indicated, acety‑
lated α‑tubulin is a read‑out for functional deacetylase activity of the different HDAC6 construct. All experiments were performed in HEK 293T cells. 
When indicated, endogenous HDAC6 expression level is shown. Data are expressed as mean ± S.E.M. of six independent experiments.
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effect against Vif-mediated A3G degradation, which 
correlated with an extent degradation of Vif (Figure  1d, 
quantitated in right panel). In contrast, the overexpres-
sion of HDAC6-ΔBUZ, lacking the C-terminal region 
that bears the Cys/His-rich BUZ motif [56], did not pro-
mote Vif degradation and strongly protected A3G from 
Vif degradation (Figure  1d, quantitated in right panel). 
This may indicate a potential interaction of HDAC6 with 
A3G, and/or an HDAC6-triggered decoupling of A3G 
from the proteasome-induced degradative action of Vif.
Interestingly, in the absence of A3G, we also observed 
that HDAC6 reduced Vif expression in a BUZ domain- 
and dose-dependent manner (Figure  2a, quantitated in 
right panel).
In cells, Vif recruits the transcription factor CBF-β 
together with EloC/B, Cul5 and Rbx to form an E3-ubiq-
uitin ligase complex. In fact, CBF-β stabilizes Vif folding 
and its proviral function in the Vif-Cul5 E3 ligase com-
plex [37, 38, 64]. In order to analyze the effect of HDAC6 
on the stability of CBF-β in the absence of A3G, we 
over-expressed Vif in HEK 293T cells and showed that 
wt-HDAC6 degrades Vif in a dose- and BUZ-dependent 
manner, without affecting endogenous CBF-β (Figure 2a, 
quantitated in right panel). Interestingly, specific knock-
down of endogenous HDAC6 by small interfering RNA 
(siRNA) enhanced the expression level of recombinant 
(Figure  2b) or proviral (Figure  2c) Vif without alter-
ing the expression of endogenous CBF-β. In parallel, we 
observed an increase on acetylated α-tubulin level (Fig-
ure 2b, c, quantitated in right panel). These results sug-
gest that the endogenous HDAC6 acts on Vif modulating 
its expression level. Indeed, HDAC6 may also protect 
A3G by targeting the Vif-Cul5 E3 ligase/CBF-β complex 
by degrading Vif, which nucleates this complex.
In the absence of Vif, A3G was not degraded by the 
overexpression of wt-HDAC6 or HDAC6-ΔBUZ con-
structs (Figure 3a). The EGFP-wt-HDAC6 construct used 
herein is functional, since it deacetylates two of its main 
substrates, Hsp90 and acetylated α-tubulin (Figure  3b), 
and inhibits HIV-1 Env-gp120-mediated α-tubulin 
acetylation in CD4  +  T cells (Figure  3c), as previously 
described [44, 45].
Taken together, our results show for the first time that 
HDAC6, through its C-terminal BUZ domain, induces 
the degradation of Vif without affecting CBF-β and pro-
tects A3G from its Vif-induced degradation.
HDAC6 interacts with A3G
We next sought to study whether HDAC6 interacts with 
A3G in the absence of Vif. By co-immunoprecipitation in 
HEK 293T cells (against A3G or endogenous HDAC6), 
we observed that A3G interacts with endogenous 
HDAC6 (Figure 4a, b). Similarly, we found that A3G co-
immunoprecipitated with overexpressed EGFP-HDAC6 
wild-type or ΔBUZ proteins (Figure 4c, d; against A3G or 
HDAC6, respectively). To ensure these results were not 
due to the tags used in A3G or HDAC6 constructs, we 
co-immunoprecipitated overexpressed HA-wt-HDAC6 
with either A3G-myc or A3G-Flag proteins, thereby con-
firming the existence of these A3G/HDAC6 interactions 
(Figure 4e). As a control for specificity, we co-immuno-
precipitated A3G-HA with Vif in HEK 293T cells and 
confirmed their binding (Figure 4f ).
Next, using fluorescence confocal microscopy, we 
observed that A3G co-distributed with endogenous 
HDAC6 or over-expressed HDAC6, either upon MT 
structures (Figure 5a, b; merged images and inset zoom 
area) where HDAC6 association occurs [44, 45, 65, 66], 
or in the cytoplasm (Figure  5c). This co-localisation 
was independent on the tag used (HA or Flag for A3G; 
EGFP and HA for HDAC6) (Figure 5b, c) and on the BUZ 
domain of HDAC6 (Figure 5c).
Taken together, this set of experiments indicates that 
HDAC6 interacts with A3G to form an HDAC6/A3G 
complex.
In order to ascertain the functional involvement of the 
C-terminal BUZ domain of HDAC6 in its interaction 
with A3G, we co-immunoprecipitated A3G against three 
different HDAC6 constructs: (A) EGFP-wt-HDAC6; (B) 
EGFP-HDAC6-ΔBUZ (lacking the BUZ domain); and 
(C) EGFP-HDAC6-BUZ (containing only the C-termi-
nal Cys/His-rich BUZ motif ) (Figure  6a) [56]. These 
co-immunoprecipitations were performed from HEK 
293T cell lysates treated with RNAse A to avoid the 
(see Figure on next page)
Figure 2 HDAC6 reduces Vif and endogenous CBF‑β expression. a Left, western blot of dose–response effects of HA‑wt‑HDAC6 and HA‑HDAC6‑
ΔBUZ (detected with anti‑HDAC6 or anti‑HA abs) on over‑expressed Vif and endogenous CBF‑β in the absence of A3G. Lanes 1, 7 and 2, 8 are con‑
trols without or with overexpressing Vif, respectively. Right, quantitation of western blots regarding HA‑HDAC6‑ and EGFP‑HDAC6‑ΔBUZ‑mediated 
Vif degradation. b, c Cell lysates from control scrambled (SCR) or siRNA‑HDAC6‑treated cells, expressing recombinant or proviral Vif (pNL4.3‑HIV‑1). 
The level of expression of Vif, proviral Pr55Gag when indicated and endogenous CBF‑β are shown in each condition. Right, histogram indicates the 
level of expression of each protein analyzed and normalized by the amount of total α‑tubulin, under any experimental condition. In all western 
blots, α‑tubulin is the control for total protein. Acetylated α‑tubulin is a read‑out for functional deacetylase activity of the remaining endogenous 
HDAC6. Endogenous HDAC6 expression level is shown. All experiments were performed in HEK 293T cells. Data are expressed as mean ± S.E.M. of six 
independent experiments.
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Figure 3 Effect of HDAC6 on A3G expression and substrate deacetylation. a Left, western blot of dose–response effects of EGFP‑wt‑HDAC6 
and EGFP‑HDAC6‑ΔBUZ (detected by anti‑HDAC6 or anti‑EGFP abs) on A3G‑3xHA expression. Right, quantitation of western blots regarding 
EGFP‑HDAC6‑ and EGFP‑HDAC6‑ΔBUZ‑mediated effect on A3G expression. All experiments were performed in HEK 293T cells. When indicated, 
endogenous HDAC6 expression level is shown. All western blots are representative of three independent experiments. b Western blot of EGFP‑wt‑
HDAC6‑mediated Hsp90 deacetylation in HEK 293T cells in a dose–response assay. Acetylated (Ac.) Hsp90 was detected from endogenous Hsp90 
pulled‑down from cell lysates and with an anti‑Hsp90 Ab, then blotted with a specific anti‑acetylated Lys Ab. c Western blot of EGFP‑wt‑HDAC6‑
mediated α‑tubulin deacetylation (compare lanes 1 and 3) and inhibition of HIV‑1 Env (rs‑gp120IIIB)‑induced acetylation of α‑tubulin (compare 
lanes 2 and 4), in a CD4 + T CEM.NKR‑CCR5 cell line. In b, c, EGFP‑wt‑HDAC6 and acetylated (Ac.) α‑tubulin were detected by anti‑EGFP and anti‑
acetylated α‑tubulin Abs, respectively. From a to c, α‑tubulin is the control for total protein. When indicated, endogenous HDAC6 expression level is 
shown. All western blots are representative of three independent experiments.
(see Figure on next page)
Figure 4 Co‑immunoprecipitation of HDAC6 and A3G. a Cell lysates from control (empty pcDNA3.1 vector) or A3G‑3xHA‑expressing HEK 293T 
cells were subjected to co‑immunoprecipitation (co‑IP) with anti‑HA Ab, followed by immunoblotting with HDAC6 and HA Abs. b Cell lysates from 
control [as in (a)] or A3G‑3xHA‑expressing cells were subjected to co‑IP with anti‑HDAC6 Ab, followed by immunoblotting with HDAC6 and HA Abs. 
c Cell‑lysates from EGFP‑wt‑HDAC6‑expressing or A3G‑3xHA/EGFP‑wt‑HDAC6‑co‑expressing cells were subjected to co‑IP with anti‑HA Ab, followed 
by immunoblotting with EGFP and HA Abs. d Cell‑lysates from A3G‑3xHA/EGFP‑wt‑HDAC6‑ or A3G‑3xHA/EGFP‑HDAC6‑ΔBUZ‑co‑expressing cells 
were subjected to co‑IP with anti‑HDAC6 Ab, followed by immunoblotting with EGFP and HA Abs. e Cell‑lysates from A3G‑Flag‑ or A3G‑myc‑
expressing cells or cells co‑expressing HA‑wt‑HDAC6 with each of the two A3G constructs were subjected to co‑IP with anti‑myc or anti‑Flag Ab, fol‑
lowed by immunoblotting with HDAC6 or A3G Abs. f Cell‑lysates from control cells (overexpressing recombinant Vif ) or A3G‑3xHA/Vif‑co‑expressing 
cells were subjected to co‑IP with anti‑HA Ab, followed by immunoblotting with Vif and HA Abs. From a to f, input expression levels of endogenous 
HDAC6 or overexpressed constructs are shown in cell lysates‑western blots from HEK 293T cells. α‑tubulin is the control for total protein. When 
detected, an IgG2a heavy chain of IgG used to pull‑down is indicated. Data are representative of three independent experiments.
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possibility that protein–protein interactions were due to 
the ability of A3G to interact with nucleic acids or to a 
potential non-specific HDAC6-associated nucleic acid 
recruitment. A3G was independently co-immunopre-
cipitated with EGFP-wt-HDAC6, EGFP-HDAC6-ΔBUZ 
and EGFP-HDAC6-BUZ constructs (Figure  6b), sug-
gesting the BUZ domain by itself is required, but not 
totally indispensable, for the HDAC6/A3G interaction. 
Thus, this could indicate that redundant A3G interacting 
motifs exist in the full-length HDAC6 protein.
HDAC6 directly interacts with A3G and Vif, and forms an 
A3G/HDAC6‑Vif complex
To further understand the involvement of HDAC6 in a 
binary (A3G/HDAC6; HDAC6-Vif ) or ternary (A3G/
HDAC6-Vif ) complex, we analyzed protein interactions 
in  vitro by GST pull-down assay (Figure  6c, GST con-
structs). First, we confirmed the interaction between 
A3G and Vif by pulling-down HA-Vif with GST-A3G 
(Figure  6d). As previously observed [67–71], two A3G 
mutants, A3G-C97A and A3G-D128K, defective in their 
Vif-induced degradation, presented a slight or a strong 
defect in their Vif binding capacity, respectively (Fig-
ure  6d, left panel). Concerning the A3G/HDAC6 inter-
action, we observed that A3G interacted with any of the 
HDAC6 constructs used in our study (Figure  6e), con-
taining or not the BUZ domain, the BUZ domain alone 
or a dead-mutant (dm) HDAC6 protein which harbours 
a double point mutation (H216A/H611A) inactivat-
ing deacetylation [44, 55, 65]. This dm-HDAC6 mutant 
was added in our study because the deacetylase activity 
of HDAC6 has been shown to be involved in promoting 
autophagosome-lysosome fusion and removal of toxic 
aggregates [47–49, 72]. The two A3G mutants, C97A and 
D128K were able to interact with any of the HDAC6 con-
structs as occurred with wt-A3G (Figure 6d, right panel). 
Thus, the binding interface between A3G and HDAC6 
could be different from the one from A3G and Vif, as 
observed with the A3G-D128K mutant. Beside, GST-Vif 
was able to pull-down all HDAC6 constructs (Figure 6e), 
thus confirming its direct interaction.
Remarkably, the BUZ domain directly interacts with 
A3G or Vif (Figure  6e). Data using the HA-HDAC6-
ΔBUZ construct indicate that regions different from the 
BUZ domain could also be involved in the HDAC6/A3G 
or Vif interactions, which could help HDAC6 to com-
pete for the A3G-Vif association thus interfering with the 
Vif-mediated A3G degradation. Hence, the BUZ domain 
seems to be responsible for efficient HDAC6/A3G inter-
action. The H216/H611 residues and subsequent deacet-
ylase activity of HDAC6, it does not seem to be required 
for the direct HDAC/A3G interaction. Hence, the 
HDAC6/A3G or HDAC6/Vif appears to be established 
through different regions of the molecule.
Altogether, these results confirm that the BUZ domain, 
together with other regions of HDAC6 (excepted the dea-
cetylase domain), are responsible for its interaction with 
A3G.
Furthermore, we showed that a ternary complex can 
be formed between HDAC6, A3G and Vif (Figure  6f; 
and scheme (2) in Figure  6g). Indeed, we showed that 
Vif could not interact with A3G-D128K (Figure  6d, left 
panel; and scheme (3) in Figure 6g), contrary to HDAC6 
that still interacted with the two A3G mutants (Figure 6d, 
right panel; and scheme (1) in Figure  6g). By using the 
GST-A3G-D128K, we observed that this A3G mutant is 
able to pull-down together HDAC6 and Vif (Figure  6f ), 
thereby indicating that a ternary A3G/HDAC6-Vif com-
plex has been established. Once more, the BUZ domain 
does not seem to be absolutely required as a ternary 
complex can still be formed with the HDAC6-ΔBUZ 
construct, even if this protein was less present in the pull-
down fractions (Figure  6f, right panel). Taken together, 
these results account for the ability of HDAC6 to form 
a ternary complex with A3G and Vif and open-up the 
possibility that HDAC6 competes for the A3G-Vif inter-
action, thus protecting A3G from its Vif proteasomal 
degradation.
Vif interacts with HDAC6/A3G
We next analyzed the effect of Vif on the forma-
tion of the HDAC6/A3G complex. For this, we 
(see Figure on next page)
Figure 5 HDAC6 and A3G co‑localize along microtubules in cells. a A series of confocal images, xy sections, shows expression patterns for endog‑
enous HDAC6 and α‑tubulin, and overexpressed A3G‑3xHA. Different merged images are shown to display endogenous HDAC6/overexpressed A3G‑
3xHA co‑distribution and co‑distribution of this complex in the cytoplasm or upon MTs (α‑tubulin). In the zoom area (black-bordered inset) is shown 
the expression of these proteins and their co‑distribution, as indicated. b Series of confocal images, xy sections, shows expression pattern for overex‑
pressed EGFP‑wt‑HDAC6 or A3G‑3xHA and α‑tubulin. Merged image is shown to display EGFP‑wt‑HDAC6/A3G‑3xHA co‑distribution in cytoplasm or 
upon MTs (α‑tubulin). In the zoom area (black-bordered inset) is shown the expression of these proteins and their co‑distribution, as indicated. c Series 
of confocal images, xy sections, shows expression pattern for overexpressed HA‑wt‑HDAC6, HA‑HDAC6‑ΔBUZ or A3G‑Flag and α‑tubulin. Merged 
image shows HA‑wt‑HDAC6/A3G‑Flag (top) or HA‑HDAC6‑ΔBUZ/A3G‑Flag (bottom) co‑distribution in cytoplasm or upon MTs (α‑tubulin). From a to 
c, data are representative of three independent experiments in HEK 293T cells.
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co-immunoprecipitated both endogenous HDAC6 and 
A3G [73, 74] from CEM.NKR.CCR5 cell lysates, in the 
absence or in the presence of overexpressed Vif pro-
tein (Figure  7a). First, these data confirm that A3G and 
HDAC6 can endogenously interact and form a constitu-
tive complex independently of Vif (Figure 7a). Although 
overexpression of Vif degraded endogenous A3G, we 
were able to co-immunoprecipitate non-degraded A3G 
and Vif proteins with HDAC6. These results indicate that 
HDAC6 interacts with A3G or with Vif, and suggest that 
the three molecules may coexist in an HDAC6-mediated 
complex, as observed above with in  vitro recombinant 
proteins (Figure 6f ).
We also seek for a potential HDAC6-Vif binding in 
HEK 293T cells overexpressing both proteins together 
with A3G (Figure 7b), and from cell lysates treated or not 
with RNAse A. We observed that HA-Vif co-immuno-
precipitates with wt-HDAC6 or HDAC6-ΔBUZ, whether 
A3G was present or not, suggesting that HDAC6 and 
Vif interact in a BUZ-independent manner (Figure  7b, 
lanes 6 and 7). Moreover, co-immunoprecipitated A3G 
could correspond to proteins that directly interact with 
Vif (Vif/A3G) (Figure  7b, lane 3), or indirectly through 
its interaction with HDAC6 (Vif-A3G/HDAC6 com-
plex) (Figure 7b, lanes 8 and 9). As previously observed 
(Figure  1d), overexpression of wt-HDAC6 in the pres-
ence of Vif induced a slight decrease in A3G expression 
(Figure  7b, compare lanes 3 and 8 in cell lysates), thus 
suggesting that HDAC6 forms a complex with A3G that 
modulates its steady-state expression in the presence of 
Vif. Moreover, all binary (Vif/A3G and Vif/HDAC6) and 
ternary (Vif-HDAC6/A3G) interactions observed above 
were direct as they were also detected from cell lysates 
treated with RNase A (Figure 7b, right panel), suggesting 
RNA is not a binding partner. Altogether, these findings 
suggest that Vif interacts with the HDAC6/A3G com-
plex through its A3G- and/or HDAC6-associated bind-
ing sites. The ability of HDAC6 to interact with Vif could 
account for the above reported HDAC6-mediated deg-
radation of Vif and A3G protection, in a BUZ domain-
dependent manner.
HDAC6 impairs Vif‑mediated A3G ubiquitination 
and proteasome degradation
Next, we analyzed the ability of Vif to promote the ubiq-
uitination and degradation of A3G in the presence of wt- 
or ΔBUZ-HDAC6, after co-transfection in HEK 293T 
cells together with Ubiquitin-6xHis. This Ubiquitin con-
struct allowed us to pull-down ubiquitinated proteins, 
and thereby obtain ubiquitinated A3G (Figure 8a). Before 
pulling-down total ubiquitinated proteins form cell 
lysates (24 h post-transfection), intact cells were treated 
with MG132 for 5  h to accumulate Vif-promoted ubiq-
uitinated A3G species. We observed that overexpression 
of wt-HDAC6 protects A3G from Vif-mediated ubiqui-
tination and degradation in a dose-dependent manner 
(Figure  8a, lanes 3 and 4). Indeed, we observed a low 
precipitation level for ubiquitinated A3G in cells over-
expressing wt-HDAC6 (Figure  8a, co-P, lanes 3 and 4), 
as previously described in cells overexpressing HDAC6 
where ubiquitinated proteins accumulated in small 
amounts prior to aggresome deaggregation and clear-
ance [50, 53]. Although HDAC6-ΔBUZ protected A3G 
against Vif-mediated degradation (Figure  8a, cell lysates 
lanes 5 and 6, and Figure 1d), it did not impede Vif-medi-
ated ubiquitination of A3G (Figure 8a, co-P, lanes 5 and 
6), correlating with the inability of the HDAC6-ΔBUZ 
mutant to recognize and clear-off ubiquitinated protein 
aggregates, in contrast to wt-HDAC6 [50].
To further confirm the protective effect exhibited by 
HDAC6 on Vif-mediated A3G ubiquitination and degra-
dation, we performed similar experiments in which endog-
enous HDAC6 was silenced by siRNA (Figure 8b). In the 
absence of Vif, we observed that specific HDAC6 siRNA 
affected neither A3G expression nor its basal ubiquitina-
tion level (Figure  8b, cell lysates and P, compare lanes 1 
(see Figure on previous page)
Figure 6 HDAC6 directly interacts with A3G and Vif to form a ternary complex. a Schematic representation of EGFP‑HDAC6 constructs used in this 
assay. The constructs are (A) EGFP‑wt‑HDAC6, (B) a construct lacking the BUZ domain (EGFP‑HDAC6‑ΔBUZ) and (C) a construct bearing the BUZ 
domain. b RNAse A‑treated cell lysates from HEK 293T cells co‑expressing A3G‑3xHA and each of the three EGFP‑HDAC6 constructs [see (a)], were 
subjected to co‑IP with anti‑EGFP Ab, followed by immunoblotting with specific Abs against EGFP or HA. Input expression levels of each EGFP‑
HDAC6 construct used and overexpressed A3G‑3xHA are shown in cell lysates‑Western blots. α‑tubulin was the control for total protein. Data shown 
are representative of three experiments. c–f Direct in vitro interaction of HDAC6 with A3G and Vif. Coomassie blue staining shows the electrophoretic 
migration profile of the recombinant GST, GST‑A3G, GST‑A3G mutants (C97A and D128K) and GST‑Vif fusion proteins (c). Recombinant GST‑proteins 
were incubated with purified in vitro translated HA‑Vif [(d), left panel] or HA‑HDAC6 proteins [(e); and (d), right panel] or both HA‑Vif and HA‑HDAC6 
proteins (f). In f, a ternary GST‑A3G‑D128K/HA‑HDAC6 construct‑HA‑Vif is shown. Bound Vif and HDAC6 proteins were fractionated on a 10% 
SDS‑PAGE, followed by immunoblotting with anti‑HA antibody (upper panels). Anti‑GST immunoblot shows the loading of the assayed GST‑fusion 
proteins (lower panels). From b to f, a representative experiment of three is shown. g A scheme showing GST‑mediated A3G‑D128K established 
interactions, as follows: (1) with HDAC6 (wt or ΔBUZ constructs); and (2) with HDAC6 (wt or ΔBUZ constructs) in the presence of Vif to form a ternary 
A3G‑D128K/HDAC6‑Vif complex. In (3) it is represented the inability of Vif to interact with A3G‑D128K.
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and 3 without Vif). However, in presence of Vif, specific 
knockdown of HDAC6 favoured Vif-mediated ubiqui-
tination of A3G (Figure 8b, compare lanes 2 and 4 in P), 
and did not protect A3G from Vif-mediated degradative 
activity (Figure 8b, compare lanes 3 and 4 in cell lysates). 
As previously observed (Figure 2b), specific knockdown of 
HDAC6 increased acetylation of α-tubulin (Figure 8b, cell 
lysates). Therefore, HDAC6, through its BUZ domain, par-
tially protects A3G by neutralizing the Vif-mediated A3G 
ubiquitination and proteasome degradation.
Figure 7 HDAC6 interacts with Vif and A3G in cells. a Cell lysates from CEM.NKR.CCR5 cells expressing endogenous A3G and HDAC6 together with 
overexpressed Vif were subjected to co‑IP with anti‑HDAC6 Ab, followed by immunoblotting with HDAC6, A3G or Vif Abs. b Cell lysates from HEK 
293T cells expressing non‑tagged A3G alone or co‑expressed with HA‑Vif, EGFP‑wt‑HDAC6 or EGFP‑HDAC6‑ΔBUZ, were subjected to co‑IP with 
anti‑HA Ab from cell lysates treated or not with RNAse A (right and left, respectively), followed by immunoblotting with HDAC6, A3G or Vif Abs. In 
a, b, actin or α‑tubulin is the control for total protein, and when detected endogenous HDAC6 and IgG Heavy‑ or Light-chains are indicated. Data 
shown are representative of three independent experiments.
(see Figure on next page)
Figure 8 HDAC6 protects A3G from Vif‑mediated ubiquitination and degradation in a BUZ domain‑dependent manner. a Cell lysates from controls 
expressing A3G‑3xHA, or lysates co‑expressing A3G‑3xHA with Vif, HA‑wt‑HDAC6 or HA‑HDAC6‑ΔBUZ were subjected to pull‑down with Ni2+‑NTA 
magnetic agarose beads to precipitate ubiquitinated proteins coupled to Ubiquitin‑6xHis (overexpressed in all experimental conditions). Co‑precip‑
itated (co‑P) extracts were immunoblotted with specific Abs directed against HA and HDAC6 to monitor co‑precipitated ubiquitinated (‑6xHis) A3G 
together with HDAC6 constructs. b Cell lysates from control scrambled or siRNA‑HDAC6‑treated cells, expressing A3G‑3xHA with or without Vif, were 
subjected to pull‑down with Ni2+‑NTA magnetic beads to precipitate ubiquitinated proteins as above. Precipitated (P) extracts were immunoblot‑
ted with a specific Ab directed against HA to monitor ubiquitinated (6xHis) A3G. HDAC6/α‑tubulin (to quantify silencing efficiency), A3G‑3xHA/α‑
tubulin and (Ubiquitinated A3G‑3xHA)/A3G‑3xHA (to quantify the increase of A3G ubiquitination) ratios are shown. In a, b, input expression levels 
of overexpressed or silenced proteins, as well as endogenous HDAC6 and α‑tubulin are shown. Data shown are representative of three independent 
experiments.
Page 13 of 26Valera et al. Retrovirology  (2015) 12:53 
Page 14 of 26Valera et al. Retrovirology  (2015) 12:53 
HDAC6 mediates Vif degradation independently of A3G‑Vif 
interaction, in an autophagy‑dependent pathway
Our data indicate that HDAC6 promotes Vif degrada-
tion, and protects A3G from its Vif-triggered proteasome 
degradation. We next analyzed the ability of HDAC6 to 
promote Vif degradation in the presence of two A3G 
mutants, such as A3G-C97A and A3G-D128K, which 
were reported to be resistant to Vif-mediated proteasome 
degradation [67–71]. We observed that HDAC6 pro-
moted Vif degradation in the presence of A3G-C97A or 
A3G-D128K mutants, which in turn were not degraded 
by Vif in cells that did not overexpress wt-HDAC6 (Fig-
ure 9a, b), suggesting that HDAC6 promotes Vif degrada-
tion independently of the ability of Vif to interact and/or 
degrade A3G.
To this end, we studied the degradative pathway trig-
gered by HDAC6, which clears-off Vif in the absence of 
A3G. We observed that HDAC6-mediated Vif degrada-
tion is blocked by 3-methyladenine (3-MA), an inhibi-
tor for autophagic sequestration of cytoplasmic proteins 
[75–77] (Figure 9c, right panel). On the contrary, overex-
pression of HDAC6 in untreated or MG132-treated cells 
triggered Vif degradation, and promoted degradation of 
p62 or sequestosome 1 (SQSTM1) (Figure 9c). This p62/
SQSTM1 protein (hereafter designated p62) connects 
ubiquitinated protein aggregates to autophagosomes, 
and also facilitates their clearance [78, 79]. Interestingly, 
an HDAC6 construct only containing the C-terminal 
BUZ domain was also able to induce Vif degradation and 
promote p62 decay (Figure  9d, left panel). This degra-
dation was inhibited by 3-MA but not by MG132 (Fig-
ure  9d). Although the MG132 inhibitor did not impede 
HDAC6-triggered degradation of Vif, it favours the 
autophagic removal of Vif by either wt-HDAC6 or the 
C-terminal BUZ domain construct (Figure 9c, d; quanti-
fied in Figure 9e). MG132 treatment of cells could favor 
the HDAC6-mediated autophagic degradation of Vif, as 
we observed. Remarkably, we did not observed p62 decay 
and Vif degradation in cells overexpressing HDAC6-
ΔBUZ (Figure  9f, left panel). Although wt-HDAC6 and 
HDAC6-ΔBUZ constructs were enzymatically functional 
as shown by the onset of α-tubulin deacetylation (Fig-
ure 9c, f ), only the HDAC6-ΔBUZ construct was unable 
to degrade Vif (Figure 9f ).
Next, we asked whether the deacetylase activity of 
HDAC6 was required to induce the reduction of Vif, as 
deacetylation was reported to be involved in promoting 
autophagosome-lysosome fusion and removal of toxic 
aggregates [49, 50]. Indeed, we observed that the deacet-
ylase mutant [(dm)-HDAC6] did not induce Vif and p62 
degradation, in accordance with a decoupling of Vif from 
the aggresome-autophagy degradation pathway (Fig-
ure  9f, right panel). Taken together, our results suggest 
that Vif is removed in an HDAC6-dependent autophagic 
pathway requiring its C-terminal BUZ domain and dea-
cetylase activity.
HDAC6‑mediated proviral Vif degradation inhibits HIV‑1 
infectiveness
Next, we analyzed the ability of HDAC6 to degrade 
HIV-1 proviral Vif and its effect on HIV-1 infective-
ness. First, in HEK 293T cells overexpressing A3G, we 
observed that Vif expressed from pNL4.3 HIV-1 pro-
virus degraded A3G in a dose-dependent manner (Fig-
ure  10a), using as a control a provirus lacking the vif 
gene. Then, we quantified the effects of HDAC6-medi-
ated proviral Vif degradation on early HIV-1 entry and 
infection by using a pNL4.3.LucR-E- provirus (bearing 
the lacZ gene) (Figure  10b) [80–83]. The overexpres-
sion of pNL4.3.LucR-E- in packaging HEK 293T cells, in 
conjunction with an X4-tropic envelope (Env) induced a 
decrease of A3G (Figure 10b, compare lane 2 with con-
trol lane 1). This effect was Vif-dependent since overex-
pression of wt-HDAC6 promoted proviral Vif decrease 
and subsequent A3G protection in a dose-dependent 
manner (Figure  10b, lanes 3 and 4). As observed above 
(Figure 1d), HDAC6-ΔBUZ protected A3G from proviral 
Vif-mediated degradation, and was unable to clear off Vif 
(Figure 10b, lanes 5 and 6).
Free-cell X4-tropic virions produced under these con-
ditions were collected to infect permissive HeLa P5 cells 
with viral synchronous doses (Figure  10b, histograms). 
(see Figure on next page)
Figure 9 The autophagic degradation of Vif is mediated by the BUZ domain and deacetylase activity of HDAC6. a, b Western blot of HDAC6‑
mediated Vif degradation in HEK 293T cells co‑expressing the A3G‑C97A (a) or A3G‑D128K (b) mutants resistant to Vif. c, d Western blot of HDAC6‑ or 
BUZ‑mediated Vif degradation concomitant with p62 analysis in HEK 293T cells co‑expressing Vif and HA‑wt‑HDAC6 or HA‑BUZ in the absence of 
A3G, or in cells treated with MG132 or 3‑MA inhibitors. e Histograms show quantification of the positive effect exerted by proteasomal inhibition 
by MG132 on wt‑HDAC6‑ and BUZ‑mediated Vif autophagic degradation. Data are from three independent western‑blot of wt‑HDAC6 and BUZ 
domain constructs, as presented in (c–d), comparing Vif/α‑tubulin ratios in Control and MG132 experimental conditions. Data are mean ± S.E.M. of 
three independent experiments carried out in triplicate: ** and * are p < 0.01 and p < 0.05, respectively, Student’s t test. f Western blot of HA‑HDAC6‑
ΔBUZ‑ and HA‑dm‑HDAC6‑effect on Vif and p62 stability in HEK 293T cells in the absence of A3G. From a to f, when indicated, control untreated 
cells, cells only expressing Vif or each A3G construct or endogenous HDAC6 are shown. When indicated, HDAC6 constructs‑deacetylase activity 
against acetylated α‑tubulin is shown. α‑tubulin is the control for total protein. Data are representative of three independent experiments.
Page 15 of 26Valera et al. Retrovirology  (2015) 12:53 
Page 16 of 26Valera et al. Retrovirology  (2015) 12:53 
We observed that HIV-1 early infection was impaired 
when wt-HDAC6 was overexpressed in packaging HEK 
293T cells, thus corresponding to conditions where Vif 
was degraded and A3G subsequently protected (Fig-
ure 10b, histograms, compare control bar in lane 2 with 
lanes 3 and 4). On the contrary, HIV-1 early infection was 
enhanced with viruses produced in HEK 293T cells over-
expressing HDAC6-ΔBUZ, where Vif level was increased 
and A3G apparently protected from Vif degradation (Fig-
ure 10b, histograms, bars in lanes 5 and 6), suggesting that 
HDAC6-ΔBUZ competes with the anti-HIV-1 activity of 
the endogenous HDAC6, thus controlling Vif expression 
level and infectiveness (Figure 10b, compare Vif and infec-
tion between lane 2 and lanes 5–6). Indeed, we observed 
a strong correlation between the amount of Vif in cells 
producing viruses and in nascent virions under these 
experimental conditions (Figure 10b, virion lysates). Sur-
prisingly, HIV-1 infectiveness was not correlated to A3G 
level, apparently stabilized by overexpressed wt-HDAC6 
or HDAC6-ΔBUZ (Figure  10b). Therefore, it seems that 
HIV-1 infectiveness correlates with Vif stability.
The anti-HIV-1 effect of HDAC6 was similarly con-
firmed with R5-tropic virions produced in HEK 293T 
cells with R5-tropic HIV-1 Env, under the same experi-
mental conditions (Figure 10c). Indeed, virions produced 
with overexpressed wt-HDAC6 were less infectious than 
control virions or virions produced in the presence of 
HDAC6-ΔBUZ (Figure  10c). Accordingly, HIV-1 infec-
tiveness was enhanced in virions produced in HEK 293T 
cells where endogenous HDAC6 was silenced, in correla-
tion with an increase amount of Vif (Figure  10d). Thus, 
there is a clear-cut and inverse correlation between the 
HDAC6 level and its degradative activity against Vif, and 
HIV-1 infectiveness.
To ascertain the HDAC6-triggered degradative path-
way for Vif, we analyzed the expression of Vif in HEK 
293T cells treated with proteasome and autophagosome/
autophagy inhibitors. We observed that the HDAC6-
mediated Vif degradation was blocked by 3-MA but not 
by MG132 (Figure  10e), without affecting its deacety-
lase activity (Figure 10e, Ac. α-tubulin). HDAC6 overex-
pression appeared to promote autophagy, as evidenced 
by a low p62 steady-state level and restored by 3-MA 
treatment (Figure  10e, see also Figure  9c), suggesting 
that HDAC6 clears-off Vif by inducing its autophagic 
degradation.
Discussion
In this study, we report for the first time that HDAC6 
represents a new cellular factor involved in HIV-1 restric-
tion. We showed that HDAC6 directly interacts with 
A3G and forms a constitutive HDAC6/A3G complex co-
distributing in the cytoplasm and along MTs, as expected 
from the ability of HDAC6 to bind MTs, either directly 
or through its association with MT-motor machinery 
[45]. Then, the binding of HDAC6 to A3G or to Vif coun-
teracts Vif activity, which in turn is unable to degrade 
A3G. Although the C-terminal BUZ domain of HDAC6 
appears to be dispensable for HDAC6/A3G interaction, 
this C-terminal region is required to promote its clear-
ance through autophagy. Moreover, HDAC6 targets Vif, 
without affecting its CBF-β E3 ligase cofactor, in a BUZ-
dependent manner. HDAC6 could exert an anti-HIV-1 
activity by stabilizing A3G by means of affecting Vif 
and the subsequent assembly of the Vif-Cul5 E3-ubiq-
uitin-ligase complex that degrades A3G [36, 38]. In fact, 
interfering with the Vif-CBF-β interaction destabilizes 
the formation and degradative activity of the Vif-Cul5 
E3-ubiquitin-ligase complex, as observed for some EloB 
mutants [38]. Similarly, the apoptosis signal-regulating 
kinase 1 (ASK1) has been shown to target Vif and block 
its interaction with EloB/C, thus affecting the E3 ligase 
(see Figure on next page)
Figure 10 HDAC6‑mediated proviral Vif degradation stabilizes A3G and impairs HIV‑1 infectiveness. a Western blot of A3G degradation by proviral 
Vif in HEK 293T cells co‑transduced with A3G‑3xHA and HIV‑1NL4.3 (dose–response) or HIV‑1 Δvif provirus. b Effect of HDAC6 on HIV‑1 infectiveness 
assayed in HeLa P5 cells incubated with equivalent luciferase‑based X4‑tropic pNL4‑3.Luc.R‑E‑ viral inputs produced in control, or in HEK 293T cells 
overexpressing A3G‑3xHA, or overexpressing HA‑wt‑HDAC6 or HA‑HDAC6‑ΔBUZ together with A3G‑3xHA. The control of infection (+) is repre‑
sented by virus produced in HEK 293T, only expressing A3G‑3xHA. A3G‑3xHA and Vif proteins incorporated into nascent virions (p24) are shown. c 
Effect of HDAC6 on HIV‑1 infectiveness, assayed in HeLa P5 cells incubated with equivalent R5‑tropic pNL4‑3.Luc.R‑E‑ viral inputs [same experimental 
conditions as in (a)], and measured by β‑galactosidase activity. d Effect of specific HDAC6 siRNA on HIV‑1 infectiveness assayed in HeLa P5 cells incu‑
bated with equivalent R5‑tropic viral inputs produced in siRNA‑HDAC6‑treated HEK 293T cells, and compared to control (+), scrambled‑treated HEK 
293T cells. HDAC6/α‑tubulin and proviral‑Vif/α‑tubulin expression ratios are shown for this representative experiment. Vif/α‑tubulin ratios from three 
independent experiments are shown in the right histogram. e Western blot of HDAC6‑mediated proviral Vif degradation concomitant with p62, 
in control HEK 293T cells transduced or not with a pNL4.3‑Luc‑R‑E‑ provirus, together with HA‑wt‑HDAC6, in the absence of A3G. 3‑MA or MG132 
treatment is shown under the same conditions. Tubulin‑deacetylase activity of HDAC6, and proviral Pr55Gag and Vif proteins are shown. All western 
blots are from a representative experiment of three, and show input expression for endogenous HDAC6 (in control, scrambled‑ or siRNA‑HDAC6‑
treated cells), overexpressed HA‑wt‑HDAC6 or HA‑HDAC6‑ΔBUZ, or A3G‑3xHA and proviral Pr55Gag, p24 and Vif proteins. Infection assay were done 
in triplicate and results are representative of four independent experiments (mean ± S.E.M.; n = 12). When indicated, α‑tubulin or actin is the control 
for total protein.
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complex formation and function [84]. HDAC6 appears 
therefore as a new natural factor that protects A3G by 
interacting with and degrading Vif.
The HDAC6/A3G interaction also occurred in pres-
ence of Vif, and resulted in a ternary A3G/HDAC6-Vif 
complex that could also be found in a BUZ-independent 
manner. Similarly, in the absence of A3G, Vif directly 
interacts with HDAC6 in a BUZ-independent manner. 
Therefore, it is conceivable that HDAC6/A3G, HDAC6-
Vif and the ternary A3G/HDAC6-Vif complexes may be 
established by different binding sites, as observed by the 
ability of various HDAC6 mutants and the BUZ domain 
to interact with A3G or Vif, being the BUZ domain 
responsible for the HDAC6-mediated degradation of Vif. 
Remarkably, the BUZ domain directly interacts with A3G 
or Vif (Figure  6e), thus confirming that HDAC6 could 
compete for the A3G-Vif interaction and target Vif for 
HDAC6-mediated aggresome-autophagic degradation, 
rescuing A3G in a BUZ dependent manner.
The HDAC6/A3G, HDAC6-Vif or HDAC6/A3G-Vif 
associations are established by direct protein–protein 
interactions and seems not to be mediated by the inter-
play of CBF-β, of any nucleic acids that could be targeted 
by Vif and/or A3G just harbouring HDAC6 into the dif-
ferent complexes. Hence, direct interaction and com-
plexes described here were confirmed by a GST-based 
in vitro protein–protein interaction system, by using pro-
tein recombinant-mediated pull-down experiments, and 
from cell lysates treated with RNAse A.
Additionally, we showed that HDAC6 protects A3G 
from Vif-mediated ubiquitination and degradation in a 
dose-dependent manner. Hence, we observed low precip-
itation levels for ubiquitinated A3G in cells overexpress-
ing HDAC6, as previously reported for ubiquitinated 
aggregates [50, 53]. Although HDAC6-ΔBUZ interacts 
and co-distributes with A3G, and appears to protect A3G 
against Vif-mediated degradation, it does not abrogate 
Vif-mediated ubiquitination of A3G. This could correlate 
with the fact that HDAC6-ΔBUZ is unable to bind free 
or protein-associated ubiquitin, or to clear ubiquitinated 
protein aggregates compared to wt-HDAC6 [50]. Simi-
lar defects have been described with C-terminal point 
mutants disrupting the ability of HDAC6 to bind ubiq-
uitin [51, 53, 58]. We observed, in presence of Vif, that 
knockdown of HDAC6 favoured Vif-mediated ubiquit-
ination and degradation of A3G, suggesting that endoge-
nous HDAC6 exerts anti-Vif activity. Thus, HDAC6 could 
protect A3G from Vif-mediated degradation by two 
cooperative actions: (1) by directly triggering Vif degra-
dation in a BUZ-dependent manner, a process that it is 
also favoured by the HDAC6-deacetylase activity; and (2) 
by forming an HDAC6/A3G complex thus decoupling 
A3G from the Vif-associated proteasomal degradation 
pathway (see Additional file  1: Summary illustration). 
This is exemplified by the HDAC6-ΔBUZ construct that 
inhibited Vif-mediated proteasomal degradation of A3G 
but failed to impair A3G ubiquitination by Vif. Thus, 
HDAC6 appears to stabilize non-ubiquitinated A3G mol-
ecules by forming an HDAC6/A3G complex. In this way, 
it controls the level of A3G expression, and clear ubiqui-
tinated A3G molecules in a dose-dependent manner. The 
ability of HDAC6 to control A3G steady-state expression 
through an HDAC6/A3G complex could be important 
for A3G immune functions, which are known to occur 
when the editing enzyme is expressed at high levels, and/
or in those infectious environments where Vif is depleted 
from virions [3, 12, 21, 26, 85–87].
The clearance of Vif by HDAC6 occurs whether Vif is 
expressed from an expression vector or from a proviral 
construct, and whether A3G is expressed or not. Moreo-
ver, HDAC6-mediated proviral Vif degradation is insen-
sitive to MG132, but is blocked by 3-MA, an inhibitor 
for autophagic sequestration of cytoplasmic proteins 
that act on class III PI3 kinase complex [75–77]. HDAC6 
also promotes degradation of p62, a molecule connect-
ing ubiquitinated protein aggregates to autophagosomes 
to facilitate their clearance [78, 79]. The p62 protein 
becomes incorporated into completed autophagosomes 
and is degraded in autolysosomes, where inhibition of 
autophagy correlates with increased p62 levels, sug-
gesting that steady-state levels of this protein reflect an 
autophagic status [77]. In contrast, HDAC6-ΔBUZ does 
not trigger p62 clearance and seems to stabilize and 
increase Vif expression, confirming the importance of 
HDAC6 in the clearance of ubiquitinated protein-aggre-
gate in a BUZ domain-dependent manner [47, 49–51]. 
These processes could be perturbed by 3-MA that alter 
the formation of the protein-sequestering autophago-
some compartment [75–77, 88], thus explaining its 
inhibitory effect on HDAC6-mediated Vif degrada-
tion (Figure 9c). In cells where proteasomal clearance is 
blocked, protein-free polyubiquitin chains are formed 
that could be recognized by HDAC6. This event acti-
vates HDAC6-triggered actinomyosin- and autophagy-
dependent aggresome processing of proteins [53], and 
could account for the MG132-mediated increase in the 
ability of wt-HDAC6 and the BUZ domain to degrade Vif 
by autophagia.
It has been reported that the deacetylase activity of 
HDAC6 is important in promoting autophasome-lys-
osome fusion and removal of toxic aggregates [47–49], 
thus deacetylase mutants of HDAC6 decouple target 
substrates from the autophagy-mediated degradation 
pathway. Here, we showed that the inactivation of the 
deacetylase domain of HDAC6 (mutant H216A/H611A) 
not only affects the deacetylation of α-tubulin [44, 55, 
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65], but also perturb the degradation of Vif by autophagy 
(Figure  9d), indicating that the deacetylase activity, in 
conjunction with the BUZ domain of HDAC6, helps 
the enzyme to form aggresomes and clears-off Vif by 
autophagy. This effect seems to be independent on the 
HDAC6/Vif interaction as HDAC6 constructs lacking the 
BUZ or the deacetylase motifs still interact with Vif (Fig-
ures 6b, 7b).
Vif uses both degradation-dependent and -independent 
mechanisms to counteract A3G antiviral activity. Indeed, 
Vif has been shown to block the encapsidation of an A3G 
mutant (A3G-C97A) without any neutralisation/degra-
dation of this mutant by Vif in cell [67]. Here, we showed 
that HDAC6 was still able to promote the degradation of 
Vif in presence of A3G-C97A and A3G-D128K mutants, 
both resistant to Vif-mediated proteasome degradation. 
Of note and as previously observed [67–71], (1) both 
mutants are resistant to Vif-mediated proteasome degra-
dation (Figure 9a), and (2) the C97A substitution, which 
abrogates A3G multimerization, does not affect its inter-
action with Vif (Figure  6d), while the D128K substitu-
tion can no longer interact with Vif (Figure 6d–f). Thus, 
HDAC6 could protect wt- or A3G mutants and degrade 
Vif independently on the ability of Vif to degrade and 
interact with A3G.
In fact, we observed a clear-cut correlation between the 
HDAC6 ability to degrade HIV-1 Vif and the restoration 
of A3G level in cells producing virions and HIV-1 infec-
tiveness, regardless viral tropism. Indeed, HIV-1 infec-
tion was impaired when viral particles were produced in 
HEK 293T cells overexpressing wt-HDAC6, where Vif is 
degraded and A3G subsequently protected. On the con-
trary, infectivity of viruses produced in HEK 293T cells 
overexpressing HDAC6-ΔBUZ was enhanced. This effect 
was not completely surprising as the BUZ domain of 
HDAC6 is required for the autophagy-mediated degra-
dation of Vif. Moreover, the fact that ubiquitinated A3G 
are increased when the BUZ domain is absent (Figure 8a) 
suggests these A3G species are not functional in their 
restrictive activity against HIV-1 (Figure  9b). Therefore, 
it appears that HIV-1 infectiveness correlates with the 
stability of Vif, which is inversely dependent on HDAC6 
expression level, rather than on the level of A3G expres-
sion. In the present work, we report that the amount of 
Vif incorporated into nascent virions correlates with their 
infectious activity, being these events directly dependent 
on the level of HDAC6 expression and on its ability to 
promote Vif autophagic degradation (Figure  10b). Thus, 
HIV-1 infectious activity is directly related to the level 
of Vif incorporated into nascent virions, rather than the 
presence of A3G (Figure 10b), as recently reported [89]. 
Of note, Vif level increased with HDAC6-ΔBUZ either 
in cells producing virions or into nascent virions, thereby 
generating more infectious virions than those derived 
from control cells. The same holds true when endog-
enous HDAC6 was knocked-down (Figure 10d). On the 
contrary, HDAC6 promotes Vif degradation and impairs 
its incorporation into nascent virions, thereby diminish-
ing viral infectivity (Figure 10b, c). Altogether these data 
indicate that HDAC6 is controlling the infectiveness of 
nascent viral particles by compromising the amount of 
Vif incorporated into the virions, a process that is inde-
pendent of the presence of A3G. Consequently, the 
anti-viral function of HDAC6 could be overcome by an 
increased expression level of Vif during viral replication.
Considering that (i) HIV-1 stabilizes acetylated micro-
tubules during the initial HIV-1 Env/CD4 contacts to 
favour pore fusion formation and infection [44, 46, 90], 
and (ii) HDAC6 plays an anti-HIV-1 replicative activ-
ity regulating this process [44–46], in conjunction 
with the impairment of both Tat proviral function (by 
HDAC6-mediated Tat deacetylation) [91] and the pro-
posed HDAC6/A3G restriction complex, the regula-
tion of HDAC6 in immune cells could represent a new 
way to overcome HIV-1 Vif proviral functions and con-
trol HIV-1 infectiveness. It is plausible that the amount 
of endogenous HDAC6 conditions the permissibility of 
cells against HIV-1 infection, first by exerting its above-
reported antiviral actions, and second, by efficiently 
forming the physiological HDAC6/A3G complex, essen-
tial for promoting A3G and HDAC6 anti-viral functions.
Conclusions
These findings led us to propose that HDAC6 and 
HDAC6/A3G may represent a natural antiviral factor 
and complex, respectively. They would be capable to 
protect the antiviral activities of A3G and promote the 
autophagic degradation of Vif, thus impairing its incor-
poration into nascent virions and HIV-1 infectiousness 
(see Additional file  1: Summary illustration). We pro-
pose HDAC6 as a new natural factor that restricts HIV-1 
infection.
Methods
Antibodies and reagents
Rabbit anti-HDAC6 (H-300; c-11420), anti-ubiquitin (FL-
76; sc-9133), anti-EGFP (FL; sc-8334) and anti-HA (sc-
805) polyclonal antibodies (polyAbs), goat APOBEC3G 
(Q17; sc-27521) polyAb, and mouse anti-HIV-1 Vif (319; 
sc-69731), anti-HA-probe (F-7; sc-7392), anti-c-myc 
(9E10; sc-40), and anti-Hsp90α/β (F-8; sc-13119), anti-
CBF-β (sc-56751) and anti-p62/SQSTM1 (D-3; sc28359) 
monoclonal Abs (mAbs), or rabbit anti-acetylated lysine 
(AB3879) polyAb were obtained from Santa Cruz Bio-
technology (Santa Cruz, CA, USA), or Millipore (Mil-
lipore Corporation, Billerica, MA, USA), respectively. 
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Rabbit anti-(HIV1 p55  +  p24  +  p17) (ab63917) pol-
yAb was purchased from Abcam (Cambridge Science 
Park, Cambridge, UK). Mouse anti-α-tubulin (clone 
B-5-1-2), anti-acetylated tubulin (clone 6-11B-1), anti-
β-actin (clone AC-74; A2228) and anti-Flag M2 (clone 
M2; F1804) mAbs, and anti-Flag (F7425) and anti-HA 
(H6908) rabbit polyAbs were obtained from Sigma-
Aldrich (Sigma-Aldrich, St. Louis, USA). Secondary 
horseradish peroxidase (HRP)-conjugated antibodies, 
specific for any antibody species assayed, were purchased 
from Dako (Glostrup, Denmark), while Alexa Fluor 
568-labeled donkey anti-goat, Alexa Fluor 488-labelled 
donkey-anti-rabbit, Alexa Fluor 633-labelled goat-
anti-mouse, Alexa Fluor 568-labeled goat-anti-rabbit, 
Alexa Fluor 633-labelled rabbit-anti-mouse, Alexa Fluor 
568-labeled donkey-anti-rabbit, Alexa Fluor 488-labeled 
rabbit-anti-goat were purchased from Molecular Probes 
(Eugene, OR, USA). Neutralizing mAb RPA-T4 (eBio-
science, San Diego, CA, USA) was directed against CD4 
and used to inhibit HIV-1 entry and infection. Endo-
toxin-free, recombinant soluble (rs) X4-tropic HIV-1 
Env-gp120-IIIB protein (rs-gp120IIIB) was produced in 
Escherichia coli by Innogenetics (Ghent, Belgium) and 
used as previously described [80, 81, 92]. MG132 (Z-Leu-
Leu-Leu-al), ALLN and 3-methyladenine (3-MA) inhibi-
tors were acquired from Sigma-Aldrich. Complete 25X 
and Phostop 10X inhibitors and the RNAse A enzyme 
were obtained from Roche Diagnostics (GmbH, Man-
nheim, Germany). TNT® Quick Coupled Transcription/
Translation System (Promega BioSciences, LLC; CA, 
USA) was used for in  vitro production of recombinant 
proteins. Monoclonal Anti-HA-Agarose antibody for 
recombinant protein purification was purchased from 
Sigma-Aldrich. Glutathione-Sepharose and pGEX-4T1 
were from Amersham Biosciences (NJ, USA). Anti-HA 
monoclonal antibody (clone 16B12) was purchased by 
Covance Antibodies (Covance, MA, USA), whereas 
mouse monoclonal anti-GST antibody (sc-138) was from 
Santa Cruz Biotechnology. For Western blotting, second-
ary horseradish peroxidase-conjugated anti-IgGs were 
from Pierce Antibodies (Thermo Fisher Scientific Inc., 
NYSE: TMO).
Cells
HEK 293T cells was grown at 37°C in a humidified 
atmosphere with 5% CO2 in DMEM (Lonza, Verviers, 
Belgium) supplemented with 10% foetal calf serum 
(Lonza), 1% l-glutamine and 1% penicillin–streptomy-
cin (Lonza). Cells were harvested, passaged every 3 days, 
and cultured to 50–70% confluence in fresh supple-
mented DMEM 24  h before cell transfection with viral 
or human DNA constructs. The HeLa-P5 cells stably 
transfected with human CD4 and CCR5 cDNAs and 
with an HIV-long terminal repeat-driven β-galactosidase 
reporter gene was provided by Dr. M. Alizon (Hôpi-
tal Cochin, Paris, France) and cultured as previously 
described [44]. The human CEM.NKR-CCR5 permis-
sive cell line (catalog number 4376, NIH AIDS Research 
and Reference Reagent Program) was grown at 37°C in 
a humidified atmosphere with 5% CO2 in RPMI 1640 
medium (Lonza) supplemented with 10% fetal calf 
serum (FCS) (Lonza), 1% l-glutamine, and 1% penicil-
lin–streptomycin antibiotics.
DNA plasmids and Viral DNA constructs
Drs. X.-J. Yang and N. R. Bertos (Molecular Oncol-
ogy Group, Department of Medicine, McGill University 
Health Centre, Montreal, Quebec, Canada) kindly pro-
vided all HDAC6 constructs used in the present study 
[56]. When indicated, these plasmids were cloned into 
pEGFP-C1 (Clontech, Palo Alto, CA, USA) or N-ter-
minal tagged with the terminal influenza hemaggluti-
nin (HA) epitope. The pcDNA3.1 (Life Technologies) 
or pEGFP-C1 (Clontech) vectors were used as a control 
of cDNA transfection or to express free EGFP, respec-
tively. APOBEC3G (A3G) was kindly provided by Dr. 
B. R. Cullen (Duke University, USA). A3G open-read-
ing frame (KpnI/EcoRI PCR fragment) was cloned first 
in frame into a pcDNA 3.1-based vector, modified to 
encode carboxy-terminal triple HA (3xHA), myc or Flag 
epitope tags. A3G-C97A and A3G-D128K expression 
vectors were obtained from wt-A3G after site-directed 
mutagenesis according to the manufacturer (Quick-
Change mutagenesis, Agilent Technology). They were 
subsequently excised using HindIII and XhoI restriction 
enzymes and cloned into the pK expression plasmid. A 
plasmid coding for Ubiquitin-6XHis was kindly pro-
vided by Dr. M. S. Rodriguez (Ubiquitin-like proteins & 
Cancer Group. Proteomics Unit. CIC bioGUNE. Parque 
Tecnológico de Vizcaya, Spain). The pNL4-3-HIV-1 and 
pNL4-3.Luc.R-E- provirus (catalog number 6070013), 
the X4-tropic HXB2-envelope (env, catalogue number 
5040154) and R5-tropic pCAGGS-SF162-gp160-env 
(catalogue number 3041817) glycoprotein vectors were 
obtained via the NIH AIDS Research and Reference Rea-
gent Programme. The HIV-1 pNL4-3 wild-type and Δvif 
proviruses were kindly provided by Dr. J. Blanco (Fun-
dació irsiCaixa-HIVACAT, Institut de Recerca en Cièn-
cies de la Salut Germans Trias i Pujol, Hospital Germans 
Trias i Pujol, Universitat Autònoma de Barcelona, Barce-
lona, Catalonia, Spain) and by Dr. O. Schwartz (Pasteur 
Institute, Paris, France), respectively. The pcDNA-hVif 
plasmid was a gift from Dr. K. Strebel (National Insti-
tute of Allergy and Infectious Diseases, Bethesda, USA). 
Full-length A3G and HIV-1-Vif cDNAs were obtained 
by PCR using the respective oligonucleotides: A3G 
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5′-TATATTGAATTCATGAAGCCTCACTTCAGA 
AACAC-3′ and 5′-TATATTCTCGAGTCAGTTTTCC 
TGATTCTGGAGAATG-3′; Vif 5′-TATATTGGATCC 
ATGGAGAACCGGTGGCAGGTG-3′ and 5′-TATAT 
TCTCGAGCTAGTGTCCATTCATTGTATGGC-3′. The 
A3G, A3G-C97A, A3G-D128K or Vif PCR products were 
cloned into pGEX-4T1 (GE), and then digested by EcoRI/
XhoI and BamHI/XhoI, respectively.
Messenger RNA silencing
Three double-stranded short interference RNA (siRNA) 
oligonucleotides (oligos) were generated (Eurogen-
tec, Hampshire, United Kingdom) against the mRNA 
sequence of HDAC6 and spanning nucleotides 193–213, 
217–237, and 284–304, as described previously [44]. One 
day before nucleofection, HEK 293T cells were grown at 
37°C in 10 cm2 plates to reach 60–80% confluence. Cells 
were then transfected with a mix of these siRNAs against 
HDAC6 (in this work referred to as siRNA-HDAC6), at a 
final total concentration of 1–1.6 μM, or by scrambled-
control oligos (1–1.6  μM) using an Amaxa nucleofec-
tor kit, an Amaxa cuvette-nucleofector device, and a 
Q-001 program (Amaxa, Lonza). Nucleofected cells from 
each experimental condition were recovered in 1 mL of 
DMEM medium and divided in two 10-cm2 plates per 
condition in a total volume medium of 10 mL, and kept 
overnight at 37°C. To analyze HDAC6 silencing, whole 
cell lysates (40 μg) of transfected cells were analyzed by 
western blot using a specific anti-HDAC6 polyAb.
Immunofluorescence
HEK 293T cells (2  ×  106) were transfected with A3G-
3xHA (1 μg), or EGFP-wt-HDAC6 (1 μg) and A3G-3xHA 
(1 μg), or HA-wt-HDAC6 (1 μg) or HA-HDAC6-ΔBUZ 
(1  μg) and A3G-3xHA or A3G-Flag (1  μg) in order to 
analyze the co-distribution of endogenous HDAC6 with 
overexpressed A3G or the co-distribution of each over-
expressed HDAC6 construct with A3G, respectively. To 
transfect cells, we used 25 kDa (PEI25k) linear polyeth-
ylenimine (Polyscience Inc., Warrington, PA, USA), as 
previously reported [82, 83]. Briefly, HDAC6 and/or A3G 
plasmids were first dissolved in 1/10th of the final tissue 
culture volume of DMEM free of serum and antibiot-
ics. PEI25k was prepared at 1 mg/mL solution in water, 
and adjusted to neutral pH. After adding PEI25k to the 
plasmids [plasmids:PEI25k ratio of 1:3 (w/w)], the solu-
tion was mixed immediately, incubated for 30  min at 
room temperature, and added to HEK 293T cells in cul-
ture. After 4  h, medium was changed to fresh DMEM 
supplemented with 10% fetal calf serum and antibiotics, 
and cells were cultivated to 60–70% confluence 24 h after 
transfection. They were then plated on sterile glass cov-
erslips [Ø, 12 mm; previously coated with poly-d-Lysine 
(0.01% in sterile H2O)] and kept in culture for 24  h at 
37°C. For immunolabelling, cells on sterile glass cov-
erslips were washed three times with PBS and fixed for 
5 min in 3% paraformaldehyde in PBS. Cells were again 
washed three times with PBS and permeabilized with 
0.1% Triton X-100 in PBS. After washing with PBS, cells 
were immunostained; in Figure  4a, with Alexa Fluor 
568-labeled donkey anti-goat against A3G (previously 
incubated with a specific goat polyAb) to detect overex-
pressed A3G-3xHA; then with Alexa Fluor 488-labelled 
donkey-anti-rabbit against HDAC6 (previously incu-
bated with a specific rabbit polyAb) to detect endogenous 
HDAC6. Endogenous α-tubulin was finally detected by 
an Alexa Fluor 633-labelled goat-anti-mouse against 
α-tubulin (previously incubated with a specific mAb). In 
Figure  4b, cells were immunostained with Alexa Fluor 
568-labeled goat-anti-rabbit against HA (previously incu-
bated with a specific rabbit polyAb) to detect overex-
pressed A3G-3xHA; then with Alexa Fluor 633-labelled 
rabbit-anti-mouse against α-tubulin (previously incu-
bated with a specific mAb). Overexpressed EGFP-wt-
HDAC6 was monitored by EGFP-associated green 
fluorescence. In Figure  4c, cells were immunostained 
with Alexa 568-labeled donkey-anti-rabbit against Flag 
(previously incubated with a specific rabbit polyAb) 
to detect overexpressed A3G-Flag; then with Alexa 
Fluor 488-labeled rabbit-anti-goat against HA (previ-
ously incubated with a specific goat polyAb) to detect 
HA-wt-HDAC6 or HA-HDAC6-ΔBUZ. Finally, cells 
were immunostained with Alexa Fluor 633-labelled rab-
bit-anti-mouse against α-tubulin (previously incubated 
with a specific mAb). Coverslips were mounted in Mow-
iol-antifade (Dako) and imaged in xy midsections with a 
FluoView FV1000 confocal microscope using a 1.35 NA 
objective (60×; Olympus, Center Valley, PA, USA) for 
high-resolution imaging of fixed cells. Final images were 
analyzed with MetaMorph software (Universal Imaging, 
Downington, PA, USA), as previously reported [83, 92].
Western blotting
Protein expression was determined in western blots of 
cell lysates. Briefly, non-treated HEK 293T cells (2 × 106) 
or those post-24  h nucleofection, were washed twice in 
phosphate-buffered saline (PBS) 1X and lysed in cold 
lysis buffer [containing 1% Triton-X-100, 50  mM Tris–
HCl pH 7,5, 150  mM  NaCl, 0,5% sodium deoxycholate, 
and protease/phosphatase inhibitors (Roche) at 1X], for 
30  min and sonicated twice for 30  s at +4°C. To ana-
lyze by western blot the effects of different inhibitors 
on HDAC6-triggered Vif (recombinant hVif or proviral 
Vif ) or endogenous CFB-β stability, we similarly assayed 
HEK 293T cells 24  h post-transfection, then treated for 
5 h at 37°C with either MG132 [20 μM; DMSO (dimethyl 
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sulfoxide) was the control vehicle] to inhibit the pro-
teasome, or 3-MA (5  mM; PBS for control samples) 
to inhibit autophagosome formation and subsequent 
autophagic degradation, monitored by detecting p62/
SQSTM1 protein. Cells were then washed twice in PBS 
1X, lysed in cold lysis buffer for 30  min, and sonicated 
twice for 30  s at +4°C. Equivalent amounts of protein 
(40 μg), measured using the bicinchoninic acid method, 
were separated by SDS-PAGE on 12% gradient gels and 
electroblotted onto 0.45  μm polyvinylidene difluoride 
membranes (PVDF; Millipore) using Trans-blot Turbo 
(Bio-Rad, Hercules, CA, USA). Membranes were probed 
with specific antibodies and the proteins recognised were 
detected by luminescence using Clarity Western ECL 
Substrate (Bio-Rad). They were then analyzed using a 
ChemiDoc MP device and Image LabTM Software, ver-
sion 4.0.1 (Bio-Rad).
Immunoprecipitation assays
HEK 293T cells (2 ×  106) were co-transfected with dif-
ferent plasmids (1 μg) using PEI25k as indicated above, 
and using non-tagged A3G, A3G-3xHA, A3G-Flag, A3G-
myc, HA-Vif (0.25 μg), and/or each HA- or EGFP-tagged 
HDAC6 construct indicated, and pcDNA3.1 or pEGFP-
C1 (0.5 μg) plasmid as a control condition. For ubiqui-
tination experiments, when indicated, MG132 (20  μM) 
inhibitor and its DMSO-vehicle control were used. 24 h 
post-transfection, cells (1 × 106/experimental condition) 
were washed twice in PBS 1X and lysed in RIPA 1X (PBS 
1X, 1% NP40, 0.5% sodium deoxycholate, 0.05% SDS) 
supplemented with protease inhibitors (complete EDTA 
Free cocktail, Roche). For HDAC6/A3G-Vif interactions, 
cells were previously treated with the proteasome inhibi-
tor ALLN (25 μM for 16  h), and then, when indicated, 
treated with RNAse A (1  mg/mL). After centrifugation, 
an input fraction (50  µL) was kept to check the protein 
expression level, and the rest was incubated for 2  h at 
4°C with 2 µg of the different Abs (anti-HA, anti-EGFP, 
anti-HDAC6, anti-A3G or anti-Flag Abs) used to immu-
noprecipitate target proteins on a rotating wheel. After 
equilibration, protein G Dynabeads (Life Technologies) 
were added and incubated for 1.5  h at 4°C. Beads were 
washed five times with cold RIPA 1X buffer on a magnet, 
and eluted in NuPAGE LDS sample buffer 1X (Life Tech-
nologies) containing 50 mM glycine pH 2.8. After 10 min 
at 70°C, immunoprecipitated supernatants were loaded 
on NuPAGE 4–12% (Life Technologies) or SDS-PAGE 
12% gradient gels, and analyzed together with the input 
cell fractions by western blot, as indicated above. To 
study the interaction of endogenous HDAC6 with endog-
enous A3G, CEM.NKR.CCR5 cells (5 ×  106) were used 
with the above experimental conditions. Moreover, when 
indicated, these cells were also nucleofected by pcDNA 
hVif vector (0.25 μg cDNA), to ascertain the existence of 
A3G/HDAC6-Vif ternary interactions.
Purification and analysis of Vif‑mediated ubiquitinated 
A3G
HEK 293T cells (2 × 106) were transfected using PEI25k, 
as indicated above, with different plasmid combinations 
or by siRNA oligos. Thus, cells were transfected by using 
A3G-3xHA (2 μg), pcDNA-hVif (1 μg), HA-wt-HDAC6 
(2 or 5 μg) or HA-HDAC6-ΔBUZ (2 or 5 μg) and Ubiq-
uitin-6xHis (4  μg), which facilitates easy detection of 
Vif-mediated A3G ubiquitination. For RNA interference 
of HDAC6, cells were transfected with siRNA-HDAC6 
oligos (1  μM) and Ubiquitin-6xHis (4  μg). pcDNA3.1 
(2 μg) or scrambled oligos (1 μM) were used as control 
conditions. As Vif could be poly-ubiquitinated by itself, 
or by the same E3 ligase [34, 63], thereby entering into 
the proteasome degradation pathway [63, 93–95], 24  h 
after transfection, cells were treated with 20  μM of 
proteasome inhibitor MG132 for 5  h at 37°C and then 
washed three times in ice-cold PBS 1X, and lysed in 1 mL 
of Lysis Buffer (100  mM NaH2PO4 pH 8, 10% glycerol, 
100 mM NaCl, 1 mM PMSF, 10 mM N-ethyl-maleimide, 
0.2% Triton-X-100, 20 mM Imidazole in double-distilled 
water) for 30  min at 4°C. Lysates were centrifuged at 
3,000×g for 15 min at 4°C and free-debris supernatants 
were collected. Protein analysis from inputs was carried 
out using these free-debris supernatants. Collected free-
debris supernatants were next assayed to immobilize 
and purify ubiquitinated-6xHis proteins, including ubiq-
uitinated overexpressed A3G-3xHA, by using Ni-NTA 
magnetic agarose beads (Qiagen, Turnberry Lane, Valen-
cia, CA, USA) (40 μL of beads per 700 μL of total super-
natant). Supernatants/Ni-NTA magnetic agarose bead 
mixes were incubated for 1  h at 4°C in a rotary shaker. 
Ni-NTA magnetic agarose beads, bearing attached 
ubiquitinated-6xHis-modified proteins, were precipi-
tated and washed by using a magnet adapter [three times 
for 2  min each in 500  μL of washing buffer (100  mM 
NaH2PO4 pH 8, 300  mM NaCl, 0.2% Triton-X-100, 
20  mM Imidazole in water)]. The remaining buffer was 
removed without disturbing the magnetic agarose beads. 
Ubiquitin-6xHis-protein complexes were eluted, and 
detached from their associated Ni-NTA magnetic aga-
rose beads, in 50 μL of elution buffer (300 mM Imidazole 
in SDS-PAGE loading buffer 2X) at room temperature 
for 30 min. Eluted ubiquitinated proteins were analyzed 
by Western blot (SDS-PAGE 8%), as indicated above. In 
conjunction with an anti-HA mAb, they then were used 
to detect ubiquitinated A3G. By using an anti-HDAC6 
rabbit polyAb, we detected HDAC6 constructs (HA-wt-
HDAC6 and HA-HDAC6-ΔBUZ) co-immobilized and 
co-precipitated with ubiquitinated A3G-3xHA proteins. 
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Non-ubiquitinated A3G-3xHA can also be precipitated 
by this method under any experimental condition. Using 
cell lysates (input), we analyzed (1) overexpressed HA-
HDAC6 constructs with an anti-HDAC6 rabbit polyAb, 
which also permitted detection of endogenous HDAC6, 
(2) A3G-3xHA with an anti-HA mAb, (3) hVif with an 
anti-Vif mAb, and (4) α-tubulin with a specific mAb.
Direct in vitro interaction assays
Full-length HA-tagged wt-HDAC6, HA-HDAC6-ΔBUZ 
and BUZ domain mutants, or HA-tagged HIV-1 Vif pro-
teins were expressed in  vitro using the rabbit-reticulo-
cytes system, whereas GST, GST-A3G (wt or its mutants) 
and GST-Vif proteins were expressed in BL21-DE3 E. 
coli cells. HA-tagged proteins were resuspended in RIPA 
1X buffer (PBS 1X, 1% NP40, 0.5% sodium deoxycho-
late, 0.05% SDS) supplemented with protease inhibitors 
(complete EDTA Free cocktail, Roche), and then purified 
using anti-HA Agarose beads following the manufactur-
er’s recommendations. For extraction of GST proteins, 
bacteria cells were lysed in Lysis Buffer (50 mM Tris–HCl 
pH 7.4, 2  mM EDTA, 150  mM NaCl, 1  mM DTT, 1% 
Triton X-100, 30 μg/mL Lysozyme, and protease inhibi-
tors) and then purified by affinity using GSH-Sepharose 
beads. 2  μg of purified HA-tagged protein were incu-
bated overnight in RIPA buffer at 4°C with 3 μg of GST, 
GST-A3G (wt, C97A or D128K mutants), or GST-Vif 
proteins immobilized on glutathione-Sepharose beads. 
Then, beads were washed three times in RIPA buffer 
and the bound cellular proteins were analyzed by West-
ern blotting using the appropriate antibodies. Hence, 
in vitro expressed, purified and pulled-down HA-tagged 
wt, ΔBUZ or BUZ constructs of HDAC6, and HIV-1 Vif 
proteins were analyzed using an anti-HA monoclonal 
antibody. Loading of GST proteins was analyzed using an 
anti-GST antibody.
Production of viral particles
Replication-deficient luciferase-HIV-1 viral particles 
were obtained as previously described [80–83, 92]; 
specifically, in HEK 293T-packaging cells that were 
also overexpressing different plasmid combinations 
of HA-HDAC6 constructs (2  μg) and/or A3G-3xHA 
(1 μg), or which had been treated with siRNA-HDAC6 
(1–1.6  μM) or scrambles oligos (1–1.6  μM). Briefly, 
replication-deficient viral particles were derived by 
the luciferase-expressing reporter virus HIV/Δnef/
Δenv/luc  +  (bearing the luciferase gene inserted into 
the nef ORF and not expressing envelope glycopro-
tein) with an X4-tropic (Lai) or R5-tropic (SF162) 
envelope glycoprotein. X4- or R5-tropic HIV-1 viral 
particles were produced by co-transfecting HEK 
293T cells (70% of confluence) in 10-cm2 dishes with 
pNL4-3.Luc.R-E- (10  μg) and X4-tropic (HXB2-env) 
or R5-tropic (pCAGGS SF162 gp160) Env glycoprotein 
(10 μg) vector and, when indicated, in cells expressing 
HA-HDAC6 constructs and/or A3G-3xHA, or treated 
with siRNA-HDAC6 or scrambled oligos. Viral plas-
mids were transduced in HEK 293T cells (12-well cul-
ture plates) using X-tremeGENE HP DNA transfection 
reagent as recommended by the manufacturer (Roche 
Diagnostics). After 6 h, medium was changed to RPMI 
1640 and supplemented with 10% FCS and antibiotics, 
with the cells then cultivated for 48 h to allow viral pro-
duction. Viruses were harvested 48 h post-transfection 
and HEK 293T cells were lysed to analyze the expression 
of Pr55Gag, proviral Vif, endogenous HDAC6 or overex-
pressed HA-HDAC6 proteins, A3G-3xHA, α-tubulin 
or actin. Supernatants containing cell-free viral par-
ticles were clarified by centrifugation at 3,000×g for 
30 min, filtered by 0.45 μm, and concentrated by Ami-
con Ultra-4 Centrifugal filter devices (Millipore). Viri-
ons were used to infect HeLa P5 cells or were stored 
at −80°C. Viral stocks were normalized by p24-Gag 
content as measured with an enzyme-linked immu-
nosorbent assay test (GenscreenTM HIV-1 Ag Assay) 
(Bio-Rad, Marnes-la-Coquette, France). To detect pro-
tein from nascent virions, supernatants from HEK 293T 
cells were centrifuged (3,000×g for 30  min), filtered 
(0.2 μm) and centrifuge for 4 h at 13,000×g. Then, total 
protein from higher density viral fraction was overnight 
precipitated by cold acetone (−20°C). Protein pellet was 
resuspended and treated by Laemmli buffer to detect 
proteins of interest (A3G, Vif and p24 on virions) by 
western blot, as above described.
Luciferase viral entry and infection assay
HeLa-P5 cells (20,000 cells in 96-well plates with 20 μg/
mL of Polybrene) were infected with a synchronous dose 
of luciferase-based X4- or R5-tropic HIV-1 viral inputs 
(500  ng of p24), in 200  μl RPMI 1640 medium for 5  h 
at 37°C. Virus was then removed by washing and sub-
sequent trypsinization of infected cells. After 48  h of 
infection, luciferase activity (associated to viruses entry 
into infected cells) was determined from cell lysates 
by using a luciferase assay kit (Biotium, Hayward, CA, 
USA) with a microplate reader (VictorTM X5, Perki-
nElmer, Waltham, MA, USA), as described [80, 83]. 
Similarly, HIV-1 infection was measured by measuring 
β-galactosidase enzymatic activity in 48  h-infected cells 
(activity associated to cell lysates from infected HeL-P5 
cells) using a β-Gal reporter gene assay (Roche Diagnos-
tics), as previously described [44, 83]. Inhibition of lucif-
erase or β-galactosidase activity was calculated for each 
dose point after subtracting background (in the presence 
of a neutralizing anti-CD4 mAb at 5  μg/mL), and the 
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background of luciferase measurement/β-galactosidase 
activity in non-infected cells. Data were analyzed using 
GraphPad Prism 5.0 software (GraphPad Software, San 
Diego, CA, USA).
Abbreviations
HDAC6: histone deacetylase 6; BUZ: bound to ubiquitin zinc finger; A3G: apoli‑
poprotein B mRNA‑editing enzyme, catalytic polypeptide‑like 3G (APOBEC3G); 
CBF‑β: core binding factor β; HIV: human immunodeficiency virus; Vif: viral 
infectivity factor.
Authors’ contribution
AV‑F designed, supervised and analyzed experiments together with J‑CP, and 
MB‑P. M‑SV, LA‑R, JB‑G, SZ, JB, ND, SM‑H, SB and LG‑E performed experiments 
and analyzed data. M‑SV, LA‑R, J‑CP and AV‑F wrote the manuscript. All 
authors read and approved the final manuscript.
Author details
1 Laboratorio de Inmunología Celular y Viral, Unidad de Farmacología, Depar‑
tamento de Medicina Física y Farmacología, Facultad de Medicina, Universidad 
de La Laguna (ULL), Campus de Ofra s/n, 38071 La Laguna, Tenerife, Spain.  
2 Architecture et Réactivité de l’ARN, CNRS, Institut de Biologie Moléculaire et 
Cellulaire, Université de Strasbourg, 15 rue René Descartes, 67084 Strasbourg, 
France. 3 Centre d’études d’agents Pathogènes et Biotechnologies pour la 
Santé (CPBS) UMR5236 CNRS UMSF, 1919 route de Mende, 34293 Montpellier 
Cedex 5, France. 
Acknowledgements
This work and A.V.‑F. are supported by the European Regional Development 
Fund (ERDF) SAF2008‑01729 and SAF2011‑24671 (MICINN and MINECO, 
respectively, Spain), UNLL10‑3E‑783 (ERDF) and Fundación CajaCanarias, 
and it has been funded by the Project RD12/0017/0034 integrated in the 
“Plan Nacional I + D + i” and co‑funded by ISCIII‑“Subdirección General de 
Evaluación” and ERDF (RIS‑RETIC), and by 24‑0740‑09 (Fundación para la Inves‑
tigación y la Prevención del SIDA en España (FIPSE), Spain) and ProID20100020 
(Agencia Canaria de Investigación, Innovación y Sociedad de la Información, 
Canary Island Government, Spain) grants. M‑S.V., L.A.‑R, J.B.‑G., and L.G.‑E. are 
supported by RD12/0017/0034‑(RIS‑RETIC)‑, SAF2011‑24671‑FPI‑, FIPSE‑24‑
0740‑09‑ and SAF2008‑01729‑associated grants and fellowships, respectively. 
Additional file
Additional file 1: Summary illustration. Model for HDAC6‑mediated A3G 
protection and control of HIV‑1 infectiveness. HDAC6 directly interacts 
and forms a constitutive complex with A3G. This HDAC6/A3G complex is 
formed either in the absence (1) or in the presence of the HIV‑1 Vif protein 
(2), and appears to be independent on the BUZ domain of HDAC6 (the 
different domains of HDAC6 are represented). Moreover, HDAC6 could 
concomitantly interact with Vif (3). The balance between the level of 
HDAC6 and Vif expression conditions the efficiency of HDAC6 to interact 
with A3G (1 and 2) and/or Vif (3 or 4; in the absence or presence of A3G, 
respectively), to avoid A3G‑Vif interaction and subsequent Vif‑mediated 
A3G ubiquitination and proteasome degradation (promoting HIV‑1 
infection) (pathway 5; the Vif‑recruited E3 ligase complex (Vif‑[CBF‑β‑
EloB‑EloC‑Cul5‑Rbx2/E2]) that targets A3G is shown). In fact, HDAC6 
induces Vif autophagic clearance in a BUZ‑dependent manner (pathway 
3), thereby inhibiting HIV‑1 infectiveness. This event is dependent on the 
HDAC6‑deacetylase activity and could be blocked by the 3‑MA inhibitor 
(6), which perturbs membrane flux during autophagosome formation; a 
process promoted early on by HDAC6 during autophagy. Hence, HDAC6 
competes for the Vif‑A3G interaction and subsequent anti‑A3G functions 
(avoiding pathway 5). HDAC6 accounts for A3G steady‑state expression 
level, stabilizing Vif‑non‑targeted forms of A3G (1). By these mechanisms, 
HDAC6 impairs HIV‑1 infectiveness by Vif clearance (pathway 6) and/
or favouring A3G‑mediated anti‑HIV‑1 functions (pathway 1). Therefore, 
HDAC6/A3G appears as a new natural restriction complex acting against 
Vif function and HIV‑1 infection.
J.‑C.P. and J.B. were supported by a grant and post‑doctoral fellowship from 
the French National Agency for Research on AIDS and Viral Hepatitis (ANRS), 
respectively. The funders had no role in study design, data collection and 
analysis, decision to publish, or preparation of the manuscript. We thank the 
National Institutes of Health AIDS Research and Reference Reagent Program 
for providing HIV‑1 plasmids and cells.
Compliance with ethical guidelines
Competing interests
The authors declare that they have no competing interests.
Received: 6 May 2014   Accepted: 10 June 2015
References
 1. Jarmuz A, Chester A, Bayliss J, Gisbourne J, Dunham I, Scott J et al (2002) 
An anthropoid‑specific locus of orphan C to U RNA‑editing enzymes on 
chromosome 22. Genomics 79:285–296
 2. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D (2003) Broad 
antiretroviral defence by human APOBEC3G through lethal editing of 
nascent reverse transcripts. Nature 424:99–103
 3. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, Gao L (2003) 
The cytidine deaminase CEM15 induces hypermutation in newly synthe‑
sized HIV‑1 DNA. Nature 424:94–98
 4. Shindo K, Takaori‑Kondo A, Kobayashi M, Abudu A, Fukunaga K, Uchiy‑
ama T (2003) The enzymatic activity of CEM15/Apobec‑3G is essential for 
the regulation of the infectivity of HIV‑1 virion but not a sole determinant 
of its antiviral activity. J Biol Chem 278:44412–44416
 5. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen‑Mahrt SK, Watt IN 
et al (2003) DNA deamination mediates innate immunity to retroviral 
infection. Cell 113:803–809
 6. Simon JH, Malim MH (1996) The human immunodeficiency virus type 1 
Vif protein modulates the postpenetration stability of viral nucleoprotein 
complexes. J Virol 70:5297–5305
 7. Gaddis NC, Chertova E, Sheehy AM, Henderson LE, Malim MH (2003) 
Comprehensive investigation of the molecular defect in vif‑deficient 
human immunodeficiency virus type 1 virions. J Virol 77:5810–5820
 8. Newman EN, Holmes RK, Craig HM, Klein KC, Lingappa JR, Malim MH et al 
(2005) Antiviral function of APOBEC3G can be dissociated from cytidine 
deaminase activity. Curr Biol 15:166–170
 9. Lecossier D, Bouchonnet F, Clavel F, Hance AJ (2003) Hypermutation of 
HIV‑1 DNA in the absence of the Vif protein. Science 300:1112
 10. Klarmann GJ, Chen X, North TW, Preston BD (2003) Incorporation of 
uracil into minus strand DNA affects the specificity of plus strand 
synthesis initiation during lentiviral reverse transcription. J Biol Chem 
278:7902–7909
 11. Mbisa JL, Barr R, Thomas JA, Vandegraaff N, Dorweiler IJ, Svarovskaia ES 
et al (2007) Human immunodeficiency virus type 1 cDNAs produced in 
the presence of APOBEC3G exhibit defects in plus‑strand DNA transfer 
and integration. J Virol 81:7099–7110
 12. Monajemi M, Woodworth CF, Benkaroun J, Grant M, Larijani M (2012) 
Emerging complexities of APOBEC3G action on immunity and viral fit‑
ness during HIV infection and treatment. Retrovirology 9:35
 13. Li J, Potash MJ, Volsky DJ (2004) Functional domains of APOBEC3G 
required for antiviral activity. J Cell Biochem 92:560–572
 14. Chiu YL, Soros VB, Kreisberg JF, Stopak K, Yonemoto W, Greene WC (2005) 
Cellular APOBEC3G restricts HIV‑1 infection in resting CD4 + T cells. 
Nature 435:108–114
 15. Li XY, Guo F, Zhang L, Kleiman L, Cen S (2007) APOBEC3G inhibits 
DNA strand transfer during HIV‑1 reverse transcription. J Biol Chem 
282:32065–32074
 16. Luo K, Wang T, Liu B, Tian C, Xiao Z, Kappes J et al (2007) Cytidine 
deaminases APOBEC3G and APOBEC3F interact with human immunode‑
ficiency virus type 1 integrase and inhibit proviral DNA formation. J Virol 
81:7238–7248
 17. Mbisa JL, Bu W, Pathak VK (2010) APOBEC3F and APOBEC3G inhibit HIV‑1 
DNA integration by different mechanisms. J Virol 84:5250–5259
Page 25 of 26Valera et al. Retrovirology  (2015) 12:53 
 18. Svarovskaia ES, Xu H, Mbisa JL, Barr R, Gorelick RJ, Ono A et al (2004) 
Human apolipoprotein B mRNA‑editing enzyme‑catalytic polypeptide‑
like 3G (APOBEC3G) is incorporated into HIV‑1 virions through interac‑
tions with viral and nonviral RNAs. J Biol Chem 279:35822–35828
 19. Wichroski MJ, Robb GB, Rana TM (2006) Human retroviral host restriction 
factors APOBEC3G and APOBEC3F localize to mRNA processing bodies. 
PLoS Pathog 2:e41
 20. Gallois‑Montbrun S, Kramer B, Swanson CM, Byers H, Lynham S, Ward M 
et al (2007) Antiviral protein APOBEC3G localizes to ribonucleoprotein 
complexes found in P bodies and stress granules. J Virol 81:2165–2178
 21. Berkhout B, de Ronde A (2004) APOBEC3G versus reverse transcriptase in 
the generation of HIV‑1 drug‑resistance mutations. AIDS 18:1861–1863
 22. Mulder LC, Harari A, Simon V (2008) Cytidine deamination induced HIV‑1 
drug resistance. Proc Natl Acad Sci USA 105:5501–5506
 23. Kim EY, Bhattacharya T, Kunstman K, Swantek P, Koning FA, Malim MH 
et al (2010) Human APOBEC3G‑mediated editing can promote HIV‑1 
sequence diversification and accelerate adaptation to selective pressure. 
J Virol 84:10402–10405
 24. Sadler HA, Stenglein MD, Harris RS, Mansky LM (2010) APOBEC3G 
contributes to HIV‑1 variation through sublethal mutagenesis. J Virol 
84:7396–7404
 25. Chiu YL, Greene WC (2006) Multifaceted antiviral actions of APOBEC3 
cytidine deaminases. Trends Immunol 27:291–297
 26. Smith HC (2011) APOBEC3G: a double agent in defense. Trends Biochem 
Sci 36:239–244
 27. Malim MH, Emerman M (2008) HIV‑1 accessory proteins—ensuring viral 
survival in a hostile environment. Cell Host Microbe 3:388–398
 28. Harris RS, Hultquist JF, Evans DT (2012) The restriction factors of human 
immunodeficiency virus. J Biol Chem 287:40875–40883
 29. Simon JH, Miller DL, Fouchier RA, Soares MA, Peden KW, Malim MH (1998) 
The regulation of primate immunodeficiency virus infectivity by Vif is cell 
species restricted: a role for Vif in determining virus host range and cross‑
species transmission. EMBO J 17:1259–1267
 30. Henriet S, Mercenne G, Bernacchi S, Paillart JC, Marquet R (2009) Tumultu‑
ous relationship between the human immunodeficiency virus type 1 
viral infectivity factor (Vif ) and the human APOBEC‑3G and APOBEC‑3F 
restriction factors. Microbiol Mol Biol Rev 73:211–232
 31. Sheehy AM, Gaddis NC, Choi JD, Malim MH (2002) Isolation of a human 
gene that inhibits HIV‑1 infection and is suppressed by the viral Vif pro‑
tein. Nature 418:646–650
 32. Marin M, Rose KM, Kozak SL, Kabat D (2003) HIV‑1 Vif protein binds 
the editing enzyme APOBEC3G and induces its degradation. Nat Med 
9:1398–1403
 33. Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P et al (2003) Induction of 
APOBEC3G ubiquitination and degradation by an HIV‑1 Vif‑Cul5‑SCF 
complex. Science 302:1056–1060
 34. Mehle A, Goncalves J, Santa‑Marta M, McPike M, Gabuzda D (2004) 
Phosphorylation of a novel SOCS‑box regulates assembly of the HIV‑1 
Vif‑Cul5 complex that promotes APOBEC3G degradation. Genes Dev 
18:2861–2866
 35. Yu Y, Xiao Z, Ehrlich ES, Yu X, Yu XF (2004) Selective assembly of HIV‑1 
Vif‑Cul5‑ElonginB‑ElonginC E3 ubiquitin ligase complex through a novel 
SOCS box and upstream cysteines. Genes Dev 18:2867–2872
 36. Guo Y, Dong L, Qiu X, Wang Y, Zhang B, Liu H et al (2014) Structural basis 
for hijacking CBF‑beta and CUL5 E3 ligase complex by HIV‑1 Vif. Nature 
505:229–233
 37. Jager S, Kim DY, Hultquist JF, Shindo K, LaRue RS, Kwon E et al (2011) Vif 
hijacks CBF‑beta to degrade APOBEC3G and promote HIV‑1 infection. 
Nature 481:371–375
 38. Wang X, Zhang H, Lv M, Zuo T, Wu H, Wang J et al (2013) Interactions 
between HIV‑1 Vif and human ElonginB–ElonginC are important for CBF‑
beta binding to Vif. Retrovirology 10:94
 39. Mariani R, Chen D, Schrofelbauer B, Navarro F, Konig R, Bollman B et al 
(2003) Species‑specific exclusion of APOBEC3G from HIV‑1 virions by Vif. 
Cell 114:21–31
 40. Stopak K, de Noronha C, Yonemoto W, Greene WC (2003) HIV‑1 Vif blocks 
the antiviral activity of APOBEC3G by impairing both its translation and 
intracellular stability. Mol Cell 12:591–601
 41. Sheehy AM, Gaddis NC, Malim MH (2003) The antiretroviral enzyme 
APOBEC3G is degraded by the proteasome in response to HIV‑1 Vif. Nat 
Med 9:1404–1407
 42. Mercenne G, Bernacchi S, Richer D, Bec G, Henriet S, Paillart JC et al (2010) 
HIV‑1 Vif binds to APOBEC3G mRNA and inhibits its translation. Nucleic 
Acids Res 38:633–646
 43. Kao S, Khan MA, Miyagi E, Plishka R, Buckler‑White A, Strebel K (2003) The 
human immunodeficiency virus type 1 Vif protein reduces intracellular 
expression and inhibits packaging of APOBEC3G (CEM15), a cellular 
inhibitor of virus infectivity. J Virol 77:11398–11407
 44. Valenzuela‑Fernandez A, Alvarez S, Gordon‑Alonso M, Barrero M, Ursa A, 
Cabrero JR et al (2005) Histone deacetylase 6 regulates human immuno‑
deficiency virus type 1 infection. Mol Biol Cell 16:5445–5454
 45. Valenzuela‑Fernandez A, Cabrero JR, Serrador JM, Sanchez‑Madrid F 
(2008) HDAC6: a key regulator of cytoskeleton, cell migration and cell‑cell 
interactions. Trends Cell Biol 18:291–297
 46. Malinowsky K, Luksza J, Dittmar MT (2008) Susceptibility to virus‑cell 
fusion at the plasma membrane is reduced through expression of HIV 
gp41 cytoplasmic domains. Virology 376:69–78
 47. Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP (2003) The 
deacetylase HDAC6 regulates aggresome formation and cell viability in 
response to misfolded protein stress. Cell 115:727–738
 48. Iwata A, Riley BE, Johnston JA, Kopito RR (2005) HDAC6 and microtubules 
are required for autophagic degradation of aggregated huntingtin. J Biol 
Chem 280:40282–40292
 49. Pandey UB, Nie Z, Batlevi Y, McCray BA, Ritson GP, Nedelsky NB et al 
(2007) HDAC6 rescues neurodegeneration and provides an essential link 
between autophagy and the UPS. Nature 447:859–863
 50. Lee JY, Koga H, Kawaguchi Y, Tang W, Wong E, Gao YS et al (2010) HDAC6 
controls autophagosome maturation essential for ubiquitin‑selective 
quality‑control autophagy. EMBO J 29:969–980
 51. Ouyang H, Ali YO, Ravichandran M, Dong A, Qiu W, MacKenzie F et al 
(2012) Protein aggregates are recruited to aggresome by histone deacet‑
ylase 6 via unanchored ubiquitin C termini. J Biol Chem 287:2317–2327
 52. Pai MT, Tzeng SR, Kovacs JJ, Keaton MA, Li SS, Yao TP et al (2007) Solu‑
tion structure of the Ubp‑M BUZ domain, a highly specific protein 
module that recognizes the C‑terminal tail of free ubiquitin. J Mol Biol 
370:290–302
 53. Hao R, Nanduri P, Rao Y, Panichelli RS, Ito A, Yoshida M et al (2013) Pro‑
teasomes activate aggresome disassembly and clearance by producing 
unanchored ubiquitin chains. Mol Cell 51:819–828
 54. Verdel A, Khochbin S (1999) Identification of a new family of higher 
eukaryotic histone deacetylases. Coordinate expression of differentiation‑
dependent chromatin modifiers. J Biol Chem 274:2440–2445
 55. Grozinger CM, Hassig CA, Schreiber SL (1999) Three proteins define a 
class of human histone deacetylases related to yeast Hda1p. Proc Natl 
Acad Sci USA 96:4868–4873
 56. Bertos NR, Gilquin B, Chan GK, Yen TJ, Khochbin S, Yang XJ (2004) Role of 
the tetradecapeptide repeat domain of human histone deacetylase 6 in 
cytoplasmic retention. J Biol Chem 279:48246–48254
 57. Seigneurin‑Berny D, Verdel A, Curtet S, Lemercier C, Garin J, Rousseaux S 
et al (2001) Identification of components of the murine histone deacety‑
lase 6 complex: link between acetylation and ubiquitination signaling 
pathways. Mol Cell Biol 21:8035–8044
 58. Hook SS, Orian A, Cowley SM, Eisenman RN (2002) Histone deacetylase 6 
binds polyubiquitin through its zinc finger (PAZ domain) and copurifies 
with deubiquitinating enzymes. Proc Natl Acad Sci USA 99:13425–13430
 59. Kovacs JJ, Hubbert C, Yao TP (2004) The HDAC complex and cytoskeleton. 
Novartis Found Symp 259:170–177 discussion 178–181, 223–175
 60. Amerik AY, Li SJ, Hochstrasser M (2000) Analysis of the deubiquitinating 
enzymes of the yeast Saccharomyces cerevisiae. Biol Chem 381:981–992
 61. Bertos NR, Wang AH, Yang XJ (2001) Class II histone deacetylases: struc‑
ture, function, and regulation. Biochem Cell Biol 79:243–252
 62. Dussart S, Courcoul M, Bessou G, Douaisi M, Duverger Y, Vigne R et al 
(2004) The Vif protein of human immunodeficiency virus type 1 is post‑
translationally modified by ubiquitin. Biochem Biophys Res Commun 
315:66–72
 63. Mehle A, Strack B, Ancuta P, Zhang C, McPike M, Gabuzda D (2004) 
Vif overcomes the innate antiviral activity of APOBEC3G by promot‑
ing its degradation in the ubiquitin‑proteasome pathway. J Biol Chem 
279:7792–7798
 64. Hultquist JF, Binka M, LaRue RS, Simon V, Harris RS (2011) Vif proteins of 
human and simian immunodeficiency viruses require cellular CBFbeta to 
degrade APOBEC3 restriction factors. J Virol 86:2874–2877
Page 26 of 26Valera et al. Retrovirology  (2015) 12:53 
 65. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A et al (2002) 
HDAC6 is a microtubule‑associated deacetylase. Nature 417:455–458
 66. Matsuyama A, Shimazu T, Sumida Y, Saito A, Yoshimatsu Y, Seigneurin‑
Berny D et al (2002) In vivo destabilization of dynamic microtubules by 
HDAC6‑mediated deacetylation. EMBO J 21:6820–6831
 67. Opi S, Kao S, Goila‑Gaur R, Khan MA, Miyagi E, Takeuchi H et al (2007) 
Human immunodeficiency virus type 1 Vif inhibits packaging and 
antiviral activity of a degradation‑resistant APOBEC3G variant. J Virol 
81:8236–8246
 68. Bogerd HP, Doehle BP, Wiegand HL, Cullen BR (2004) A single amino acid 
difference in the host APOBEC3G protein controls the primate species 
specificity of HIV type 1 virion infectivity factor. Proc Natl Acad Sci USA 
101:3770–3774
 69. Mangeat B, Turelli P, Liao S, Trono D (2004) A single amino acid determi‑
nant governs the species‑specific sensitivity of APOBEC3G to Vif action. J 
Biol Chem 279:14481–14483
 70. Xu H, Svarovskaia ES, Barr R, Zhang Y, Khan MA, Strebel K et al (2004) 
A single amino acid substitution in human APOBEC3G antiretroviral 
enzyme confers resistance to HIV‑1 virion infectivity factor‑induced 
depletion. Proc Natl Acad Sci USA 101:5652–5657
 71. Batisse J, Guerrero SX, Bernacchi S, Richert L, Godet J, Goldschmidt V et al 
(2013) APOBEC3G impairs the multimerization of the HIV‑1 Vif protein in 
living cells. J Virol 87:6492–6506
 72. Dompierre JP, Godin JD, Charrin BC, Cordelieres FP, King SJ, Humbert S 
et al (2007) Histone deacetylase 6 inhibition compensates for the trans‑
port deficit in Huntington’s disease by increasing tubulin acetylation. J 
Neurosci 27:3571–3583
 73. Zhou T, Han Y, Dang Y, Wang X, Zheng YH (2009) A novel HIV‑1 restriction 
factor that is biologically distinct from APOBEC3 cytidine deaminases in a 
human T cell line CEM.NKR. Retrovirology 6:31
 74. Zhou T, Dang Y, Baker JJ, Zhou J, Zheng YH (2012) Evidence for Vpr‑
dependent HIV‑1 replication in human CD4 + CEM.NKR T‑cells. Retrovi‑
rology 9:93
 75. Seglen PO, Gordon PB (1982) 3‑Methyladenine: specific inhibitor of 
autophagic/lysosomal protein degradation in isolated rat hepatocytes. 
Proc Natl Acad Sci USA 79:1889–1892
 76. Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, Hibshoosh H et al 
(1999) Induction of autophagy and inhibition of tumorigenesis by beclin 
1. Nature 402:672–676
 77. Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, Askew DS et al 
(2008) Guidelines for the use and interpretation of assays for monitoring 
autophagy in higher eukaryotes. Autophagy 4:151–175
 78. Bjorkoy G, Lamark T, Johansen T (2006) p62/SQSTM1: a missing link 
between protein aggregates and the autophagy machinery. Autophagy 
2:138–139
 79. Pankiv S, Clausen TH, Lamark T, Brech A, Bruun JA, Outzen H et al 
(2007) p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degrada‑
tion of ubiquitinated protein aggregates by autophagy. J Biol Chem 
282:24131–24145
 80. Barrero‑Villar M, Barroso‑Gonzalez J, Cabrero JR, Gordon‑Alonso M, 
Alvarez‑Losada S, Munoz‑Fernandez MA et al (2008) PI4P5‑kinase Ialpha 
is required for efficient HIV‑1 entry and infection of T cells. J Immunol 
181:6882–6888
 81. Barrero‑Villar M, Cabrero JR, Gordon‑Alonso M, Barroso‑Gonzalez J, 
Alvarez‑Losada S, Munoz‑Fernandez MA et al (2009) Moesin is required 
for HIV‑1‑induced CD4‑CXCR4 interaction, F‑actin redistribution, mem‑
brane fusion and viral infection in lymphocytes. J Cell Sci 122:103–113
 82. Barroso‑Gonzalez J, El Jaber‑Vazdekis N, Garcia‑Exposito L, Machado JD, 
Zarate R, Ravelo AG et al (2009) The lupane‑type triterpene 30‑oxo‑
calenduladiol is a CCR5 antagonist with anti‑HIV‑1 and anti‑chemotactic 
activities. J Biol Chem 284:16609–16620
 83. Garcia‑Exposito L, Barroso‑Gonzalez J, Puigdomenech I, Machado JD, 
Blanco J, Valenzuela‑Fernandez A (2011) HIV‑1 requires Arf6‑mediated 
membrane dynamics to efficiently enter and infect T lymphocytes. Mol 
Biol Cell 22:1148–1166
 84. Miyakawa K, Matsunaga S, Kanou K, Matsuzawa A, Morishita R, Kudoh A 
et al (2015) ASK1 restores the antiviral activity of APOBEC3G by disrupting 
HIV‑1 Vif‑mediated counteraction. Nat Commun 6:6945
 85. Pillai SK, Wong JK, Barbour JD (2008) Turning up the volume on muta‑
tional pressure: is more of a good thing always better? (A case study of 
HIV‑1 Vif and APOBEC3). Retrovirology 5:26
 86. Chiu YL, Greene WC (2008) The APOBEC3 cytidine deaminases: an innate 
defensive network opposing exogenous retroviruses and endogenous 
retroelements. Annu Rev Immunol 26:317–353
 87. Roberts SA, Lawrence MS, Klimczak LJ, Grimm SA, Fargo D, Stojanov 
P et al (2013) An APOBEC cytidine deaminase mutagenesis pattern is 
widespread in human cancers. Nat Genet 45:970–976
 88. Kovacs AL, Rez G, Palfia Z, Kovacs J (2000) Autophagy in the epithelial 
cells of murine seminal vesicle in vitro. Formation of large sheets of nas‑
cent isolation membranes, sequestration of the nucleus and inhibition by 
wortmannin and 3‑ethyladenine. Cell Tissue Res 302:253–261
 89. Wang Y, Kinlock BL, Shao Q, Turner TM, Liu B (2014) HIV‑1 Vif inhibits G 
to A hypermutations catalyzed by virus‑encapsidated APOBEC3G to 
maintain HIV‑1 infectivity. Retrovirology 11:89
 90. Sabo Y, Walsh D, Barry DS, Tinaztepe S, de Los Santos K, Goff SP (2013) 
HIV‑1 induces the formation of stable microtubules to enhance early 
infection. Cell Host Microbe 14:535–546
 91. Huo L, Li D, Sun X, Shi X, Karna P, Yang W et al (2011) Regulation of tat 
acetylation and transactivation activity by the microtubule‑associated 
deacetylase HDAC6. J Biol Chem 286:9280–9286
 92. Garcia‑Exposito L, Ziglio S, Barroso‑Gonzalez J, de Armas‑Rillo L, Valera 
MS, Zipeto D et al (2013) Gelsolin activity controls efficient early HIV‑1 
infection. Retrovirology 10:39
 93. Akari H, Fujita M, Kao S, Khan MA, Shehu‑Xhilaga M, Adachi A et al 
(2004) High level expression of human immunodeficiency virus type‑1 
Vif inhibits viral infectivity by modulating proteolytic processing of the 
Gag precursor at the p2/nucleocapsid processing site. J Biol Chem 
279:12355–12362
 94. Izumi T, Takaori‑Kondo A, Shirakawa K, Higashitsuji H, Itoh K, Io K et al 
(2009) MDM2 is a novel E3 ligase for HIV‑1 Vif. Retrovirology 6:1
 95. Mehle A, Wilson H, Zhang C, Brazier AJ, McPike M, Pery E et al (2007) Iden‑
tification of an APOBEC3G binding site in human immunodeficiency virus 
type 1 Vif and inhibitors of Vif‑APOBEC3G binding. J Virol 81:13235–13241
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
